var title_f20_51_21296="Superficial partial thick burn";
var content_f20_51_21296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial partial-thickness burn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blistering burns that blanch with pressure characterize superficial partial-thickness burns. They are also typically moist and weep.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Morgan and William F Miser, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_51_21296=[""].join("\n");
var outline_f20_51_21296=null;
var title_f20_51_21297="Cervical spine contour lines";
var content_f20_51_21297=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical spine contour lines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 264px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Anterior vertebral line. (B) Posterior vertebral line. (C) Spinolaminal line. (D) Tips of the spinous processes. (1) Dens of C2. (2) Anterior arch of C1. (3) Predental space.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Barkin, RM, Rosen, P, Emergency Pediatrics: A Guide to Ambulatory Care, 5th ed, Mosby, St Louis 1999. p.455. Copyright &copy; 1999 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_51_21297=[""].join("\n");
var outline_f20_51_21297=null;
var title_f20_51_21298="EB nevi 5";
var content_f20_51_21298=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Epidermolysis bullosa nevi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Papular components arising within an EB nevus in a 35-year-old patient with junctional EB.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_51_21298=[""].join("\n");
var outline_f20_51_21298=null;
var title_f20_51_21299="Finger flexion";
var content_f20_51_21299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Finger flexion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows the muscles and tendons involved in flexion of the distal and middle interphalangeal joints.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anatomical Chart Company, General Anatomy. Copyright &copy;2008 Anatomical Chart Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_51_21299=[""].join("\n");
var outline_f20_51_21299=null;
var title_f20_51_21300="Complementary and alternative medicine treatments (CAM) for cancer";
var content_f20_51_21300=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?20/51/21300/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/51/21300/contributors\" id=\"au5060\">",
"       Edzard Ernst, MD, PhD, FMEdSci, FSB, FRCP, FRCP (Edin.)",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?20/51/21300/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/51/21300/contributors\" id=\"se4185\">",
"       Reed E Drews, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?20/51/21300/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/51/21300/contributors\" id=\"de5563\">",
"       Diane MF Savarese, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?20/51/21300?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      COMPLEMENTARY AND ALTERNATIVE MEDICINE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Complementary and alternative medicine (CAM) is defined by the National Center for Complementary and Alternative Medicine as \"a group of diverse medical and healthcare systems, practices, and products that are not presently considered to be part of conventional medicine\" [",
"     <a class=\"abstract\" href=\"UTD.htm?20/51/21300/abstract/1\">",
"      1",
"     </a>",
"     ]. For some CAM practices, there is scientific evidence that a treatment is both beneficial and safe. For many other practices, evidence is negative, lacking, or inconclusive.",
"    </p>",
"    <p>",
"     A large percentage of people with cancer use some form of CAM. Most patients who use CAM are not dissatisfied with conventional medicine but find that CAM treatments appeal to their values and beliefs about health and life. Being diagnosed with cancer and undergoing treatment is a frightening, exhausting, and demanding experience. CAM appeals to many patients with cancer because these treatments often offer a chance to take control, feel better, and decrease uncomfortable symptoms such as pain, fatigue, and nausea.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2\">",
"     <span class=\"h2\">",
"      Placebo effect",
"     </span>",
"     &nbsp;&mdash;&nbsp;The concept of a placebo effect is important to understand when trying to evaluate the benefit of interventions for cancer and cancer treatment-related symptoms. A placebo is an inactive medication or treatment. Well-designed comparative studies include a placebo treatment, as well as a \"real\" treatment, so that the two may be compared. For example, a CAM treatment that claims to improve symptoms of nausea in 50 percent of patients is of little benefit if the placebo treatment also improves symptoms in 50 percent of patients.",
"    </p>",
"    <p>",
"     The placebo effect is not well understood but has a strong influence on the results of any research study, whether in conventional or complementary medicine.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      COMPLEMENTARY MEDICINE",
"     </span>",
"    </p>",
"    <p>",
"     Complementary medicine is a treatment, practice, or product that is used alongside conventional medical treatment. It is not meant to replace conventional cancer treatment but is available to alleviate side effects or improve a patient's sense of well being.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Alternative medical systems",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alternative medical systems are healing techniques and beliefs that have developed over time and include homeopathy, naturopathy, and traditional Chinese medicine (which includes acupuncture).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Acupuncture",
"     </span>",
"     &nbsp;&mdash;&nbsp;Acupuncture involves inserting thin metal needles into the skin at specific points on the body. It causes little to no pain. Electrical stimulation is sometimes applied to the acupuncture needle. There have been numerous studies of acupuncture's efficacy in reducing nausea, pain, dry mouth after radiation treatment for head and neck cancer, and hot flashes, and results have been mixed.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Acupuncture with electrical stimulation has been found to be useful in treating nausea and vomiting from chemotherapy.",
"      </li>",
"      <li>",
"       Some trials suggest that acupuncture can reduce cancer pain, although a review of multiple trials showed it to be of no benefit.",
"      </li>",
"      <li>",
"       In one trial, the use of acupuncture significantly reduced mouth pain and the sensation of dry mouth in a group of patients undergoing radiation therapy for head and neck cancer.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H646180\">",
"     <span class=\"h3\">",
"      Traditional Chinese medicine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other forms of traditional Chinese medicine, which use standard combinations of herbs or botanicals for various illnesses, are difficult to study. Chinese herbal medicines are widely used in many areas of Asia to reduce the toxicity associated with conventional anticancer therapy; however, little information is available from controlled studies regarding the safety and efficacy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Mind-body techniques",
"     </span>",
"     &nbsp;&mdash;&nbsp;Mind-body techniques include practices such as hypnosis, guided imagery, meditation, yoga, biofeedback, and prayer. These techniques may be useful before or during painful or stress-inducing medical procedures, chemotherapy, or radiation treatment to control anxiety, pain, or nausea and vomiting. Patients of any age can learn mind-body techniques.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Hypnotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hypnosis is a state of altered consciousness that allows you to focus away from your pain, anxiety, or nausea. You are not sleeping while hypnotized but are actually in a state of heightened imagination, similar to daydreaming. An expert can hypnotize an individual, or you can learn self-hypnosis techniques. Hypnosis is safe and has few side effects.",
"    </p>",
"    <p>",
"     It is not clear how or if hypnosis is helpful, although studies have suggested that it may be useful for controlling pain and",
"     <span class=\"nowrap\">",
"      nausea/vomiting",
"     </span>",
"     in various settings and may reduce vomiting that can develop before starting chemotherapy (called anticipatory emesis).",
"    </p>",
"    <p>",
"     One study examined the benefit of hypnosis before surgery for breast cancer [",
"     <a class=\"abstract\" href=\"UTD.htm?20/51/21300/abstract/2\">",
"      2",
"     </a>",
"     ]. They found that women who had a 15-minute hypnosis session before surgery had less pain, nausea, and fatigue after surgery, and they required significantly less time in the operating room compared with women who were not hypnotized. It is not clear whether some of these benefits represent placebo effects.",
"    </p>",
"    <p>",
"     Hypnosis may also be useful in children for preventing anxiety and pain from difficult procedures, such as lumbar puncture (spinal tap) or bone marrow biopsy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Visual or guided imagery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Visual or guided imagery is a technique that encourages the patient to relax by focusing on calming thoughts or experiences. You sit or lie in a comfortable position while imagining a pleasant experience, such as relaxing on the beach. In one study, women receiving chemotherapy for newly diagnosed breast cancer had a better quality of life if they used relaxation training and guided imagery, as compared with a group that had chemotherapy alone [",
"     <a class=\"abstract\" href=\"UTD.htm?20/51/21300/abstract/3\">",
"      3",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Spirituality",
"     </span>",
"     &nbsp;&mdash;&nbsp;A majority of individuals have religious beliefs, and many people rely on their religion or spirituality in difficult times, such as during treatments for cancer [",
"     <a class=\"abstract\" href=\"UTD.htm?20/51/21300/abstract/4\">",
"      4",
"     </a>",
"     ]. Researchers found that spirituality, when combined with conventional medicine, was an important component in the healing process and was of benefit not only to the patient but also to caregivers and healthcare professionals [",
"     <a class=\"abstract\" href=\"UTD.htm?20/51/21300/abstract/5\">",
"      5",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Some, but not all, studies have shown that religious involvement and spirituality are associated with better health outcomes, including longer life, improved coping skills, better health in general, and lower rates of anxiety, depression, and suicide [",
"     <a class=\"abstract\" href=\"UTD.htm?20/51/21300/abstract/6\">",
"      6",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Body-based therapies",
"     </span>",
"     &nbsp;&mdash;&nbsp;Body-based therapies use movement or manipulation of one or more parts of the body.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Massage therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Massage involves stroking and kneading the skin, muscles, and connective tissues. There are several types of massage therapy.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Classic or Swedish massage is aimed primarily at muscles. It reduces tension and increases blood flow.",
"      </li>",
"      <li>",
"       Reflexology is massage of the hands and feet based on a system of points that are claimed to correlate to other areas of the body.",
"      </li>",
"      <li>",
"       Chair massage is done while the patient sits fully clothed in a special chair that slopes forward, allowing the therapist access to the back, neck, and shoulders.",
"      </li>",
"      <li>",
"       Deep tissue massage is a form of intense tissue manipulation.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A study was done in 1,290 cancer patients who received massage therapy at Memorial Sloan-Kettering Cancer Center. It found that pain, anxiety, fatigue, and nausea decreased by 50 percent in patients who received massage. Some patients reported benefits lasting up to 48 hours [",
"     <a class=\"abstract\" href=\"UTD.htm?20/51/21300/abstract/7\">",
"      7",
"     </a>",
"     ]. A small number of insurance companies cover massage therapy as a complementary cancer treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Energy therapies",
"     </span>",
"     &nbsp;&mdash;&nbsp;Energy therapies involve using assumed energy fields to heal and maintain wellness. Believers in energy medicine describe disruptions in the energy field as a cause for illness and teach that balancing energy can aid in healing. It is difficult to study the effectiveness of energy medicine due to the intangible nature of the body's \"energy\".",
"    </p>",
"    <p>",
"     Reiki is a form of energy medicine and has been evaluated in several clinical trials for treatment of anxiety and improvement of well-being in cancer patients. Some, but not all, trials showed positive results, although the studies showing benefit were not well designed, and it is difficult to distinguish the true benefit from placebo effect.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      ALTERNATIVE CANCER TREATMENTS",
"     </span>",
"    </p>",
"    <p>",
"     Alternative cancer treatments (ACTs) are usually promoted as replacements to conventional cancer treatments. Cancer patients may seek them out in the hope of a cure. Some ACTs require the patient to receive treatment at their clinics, often located outside the United States. In many cases, reliable clinical trials have found these treatments ineffective or unsafe, and the FDA has not given approval for these treatments inside the United States.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Dietary ACTs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Good nutrition is important for cancer patients. However, none of the dietary ACTs are proven to prolong life or cure cancer. In addition, some alternative cancer diet treatments are costly and potentially harmful.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Gerson regimen",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Gerson regimen requires an organic, vegetarian diet and includes a strict schedule for ingesting juice made from fruits and vegetables. In addition, patients are given a number of vitamin supplements. No clinical study has proven this regimen's efficacy. It is not recommended and may be expensive and harmful.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Macrobiotic diets",
"     </span>",
"     &nbsp;&mdash;&nbsp;Macrobiotic diets are low-fat, vegetarian diets that include large amounts of complex carbohydrates. One report found that one-third of cancer patients who followed a macrobiotic diet lost weight, which resulted in other problems [",
"     <a class=\"abstract\" href=\"UTD.htm?20/51/21300/abstract/8\">",
"      8",
"     </a>",
"     ]. This was likely due to several factors, including the expense or inaccessibility of some of the required foods, time spent preparing the meals, and the restrictive, sometimes unpleasant, nature of the diet. Macrobiotic diets are not recommended for people with cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Selected vegetables",
"     </span>",
"     &nbsp;&mdash;&nbsp;Selected vegetables (SV), also called Sun's Soup, is a blended, boiled, and freeze-dried product that claims to have immune-stimulatory and anticancer properties. Two small studies have been conducted in patients with late-stage non-small-cell lung cancer, both of which found that patients who received the supplement had an improved survival. Patients in both studies received conventional medical treatments, as well as the SV mix. However, the studies were small and had weaknesses in study design; further studies are needed before the treatment can be considered safe and effective.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Herbal medicine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Combinations of herbs (also called botanicals) are often promoted as ACTs. Herbal medicines may come in the form of a powder, liquid, or pill. Examples of herbal treatments include essiac, ginseng, green tea, Flor Essence tea, mistletoe, PC-SPES (a mixture of herbs marketed for prostate cancer, now recalled due to an increased risk of blood clots), sho-saik-to, and St. John's wort [",
"     <a class=\"abstract\" href=\"UTD.htm?20/51/21300/abstract/9\">",
"      9",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     None of these herbals have been proven to cure or improve cancer in reliable clinical studies; some can cause dangerous side effects. In addition, some herbal products (particularly St. John&rsquo;s wort) can interact with conventional cancer treatments, making conventional treatments less effective [",
"     <a class=\"abstract\" href=\"UTD.htm?20/51/21300/abstract/9\">",
"      9",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Other supplements",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of dietary supplements have been advertised as being useful ACTs. These include coenzyme Q10, hydrazine, melatonin, shark cartilage, shiitake mushroom extract, and thymus extract. No supplement has proven reliable as either an alternative or complement to conventional cancer treatment [",
"     <a class=\"abstract\" href=\"UTD.htm?20/51/21300/abstract/9\">",
"      9",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      PATIENTS CONSIDERING CAM",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      General recommendations",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anyone who is considering use of a complementary, alternative, or conventional medical treatment should gather information about the safety, risks, and benefits of the treatment. Reliable information sources include the healthcare team (clinician, nurse, dietitian) and government-sponsored Web sites.",
"    </p>",
"    <p>",
"     It is important to choose the person providing CAM with care; you should inquire about education and licensing requirements, since these vary by state. The safety of CAM treatments should be considered. Being \"natural\" does not mean that a product or treatment is safe.",
"    </p>",
"    <p>",
"     The cost of a CAM treatment must also be considered, as these treatments are generally not covered by commercial or government-funded health insurance. A patient or family who uses its life's savings for an unproven \"cure\" is likely to be disappointed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Questions to consider",
"     </span>",
"     &nbsp;&mdash;&nbsp;When evaluating an alternative or complementary treatment, consider the following questions:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Does the treatment require patients to stop conventional medical care?",
"      </li>",
"      <li>",
"       Does it claim to cure cancer?",
"      </li>",
"      <li>",
"       Is it offered by only one individual or by an established, recognized cancer treatment facility?",
"      </li>",
"      <li>",
"       Is it a secret that only certain people can share?",
"      </li>",
"      <li>",
"       Does it require travel to another country? Is it approved in the United States?",
"      </li>",
"      <li>",
"       Is it based on well-controlled, scientific research?",
"      </li>",
"      <li>",
"       Is it expensive?",
"      </li>",
"      <li>",
"       Is the group or person promoting the CAM treatment an expert in cancer treatment?",
"      </li>",
"      <li>",
"       Do the promoters attack the scientific and medical research community?",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Combining CAM and conventional treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients who are considering a CAM treatment must consider the safety and potential benefit of the treatment itself and must also consider how the CAM treatment could interact with conventional treatments, such as chemotherapy.",
"    </p>",
"    <p>",
"     It is possible for a CAM treatment, especially a dietary ACT, herbal medicine, or other supplement, to alter the body's metabolism and clearance of chemotherapy in unexpected ways. Because CAM treatments are not generally tested for use in combination with standard chemotherapy, they could interfere with the beneficial effect of the chemotherapy or potentially increase the risk of toxic side effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8596182\">",
"     <span class=\"h2\">",
"      Refusing or delaying conventional treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients should be very careful about refusing or delaying conventional treatment in order to receive CAM treatment instead. A recent study showed that women with breast cancer who refused or delayed surgery in favor of CAM were much more likely to have cancer progression and to die of their disease than they would have had they undergone immediate surgery. Similarly, women who did not follow through with hormone therapy, chemotherapy, or radiation as directed were much more likely to have cancer progression or die of cancer than they would have had they undergone the recommended treatment [",
"     <a class=\"abstract\" href=\"UTD.htm?20/51/21300/abstract/10\">",
"      10",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11480109\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11480117\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=see_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/33/25105?source=see_link\">",
"      Patient information: Alternative medicine (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/62/27618?source=see_link\">",
"      Patient information: Probiotics (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11480125\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Beyond the Basics content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h3\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=see_link\">",
"      Acupuncture",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7607?source=see_link\">",
"      Acupuncture for rheumatic conditions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23542?source=see_link\">",
"      Clinical use of echinacea",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/28/11720?source=see_link\">",
"      Clinical use of ginkgo biloba",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33061?source=see_link\">",
"      Clinical use of saw palmetto",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27784?source=see_link\">",
"      Clinical use of St. John's wort",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7513?source=see_link\">",
"      Complementary and alternative remedies in rheumatic disorders",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=see_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25642?source=see_link\">",
"      Hepatotoxicity due to herbal medications and dietary supplements",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"      Menopausal hot flashes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6933?source=see_link\">",
"      Nephropathy induced by aristolochic acid (AA) containing herbs",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/treatment/cam\">",
"      www.cancer.gov/cancertopics/treatment/cam",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Center for Complementary and Alternative Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.nccam.nih.gov/\">",
"      www.nccam.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Natural Standard",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.naturalstandard.com/\">",
"      www.naturalstandard.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Memorial Sloan-Kettering Cancer Center",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.mskcc.org/mskcc/html/1979.cfm\">",
"      www.mskcc.org/mskcc/html/1979.cfm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?20/51/21300/abstract/1,3-9,11-14\">",
"      1,3-9,11-14",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?20/51/21300?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21300/abstract/1\">",
"      NIH Consensus Conference. Acupuncture. JAMA 1998; 280:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21300/abstract/2\">",
"      Montgomery GH, Bovbjerg DH, Schnur JB, et al. A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients. J Natl Cancer Inst 2007; 99:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21300/abstract/3\">",
"      Walker LG, Walker MB, Ogston K, et al. Psychological, clinical and pathological effects of relaxation training and guided imagery during primary chemotherapy. Br J Cancer 1999; 80:262.",
"     </a>",
"    </li>",
"    <li>",
"     www.cancer.gov (Accessed on January 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21300/abstract/5\">",
"      Rummans TA, Clark MM, Sloan JA, et al. Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. J Clin Oncol 2006; 24:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21300/abstract/6\">",
"      Mueller PS, Plevak DJ, Rummans TA. Religious involvement, spirituality, and medicine: implications for clinical practice. Mayo Clin Proc 2001; 76:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21300/abstract/7\">",
"      Cassileth BR, Vickers AJ. Massage therapy for symptom control: outcome study at a major cancer center. J Pain Symptom Manage 2004; 28:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21300/abstract/8\">",
"      Downer SM, Cody MM, McCluskey P, et al. Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 1994; 309:86.",
"     </a>",
"    </li>",
"    <li>",
"     Ernst E, Pittler MH, Wider B, Boddy K. The desktop guide to complementary and alternative medicine, Edinburgh 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21300/abstract/10\">",
"      Han E, Johnson N, DelaMelena T, et al. Alternative therapy used as primary treatment for breast cancer negatively impacts outcomes. Ann Surg Oncol 2011; 18:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21300/abstract/11\">",
"      Ezzo J, Vickers A, Richardson MA, et al. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol 2005; 23:7188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21300/abstract/12\">",
"      Lee H, Schmidt K, Ernst E. Acupuncture for the relief of cancer-related pain--a systematic review. Eur J Pain 2005; 9:437.",
"     </a>",
"    </li>",
"    <li>",
"     The National Center for Complementary and Alternative Medicine, publications available online. www.nccam.nih.gov (Accessed on January 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21300/abstract/14\">",
"      Ernst E. Intangible risks of complementary and alternative medicine. J Clin Oncol 2001; 19:2365.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f20_51_21300=[""].join("\n");
var outline_f20_51_21300=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           COMPLEMENTARY AND ALTERNATIVE MEDICINE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           COMPLEMENTARY MEDICINE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           ALTERNATIVE CANCER TREATMENTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           PATIENTS CONSIDERING CAM",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f20_51_21301="Calcium acetate: Pediatric drug information";
var content_f20_51_21301=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcium acetate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39685?source=see_link\">",
"    see \"Calcium acetate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/38/7780?source=see_link\">",
"    see \"Calcium acetate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eliphos&trade;;",
"     </li>",
"     <li>",
"      PhosLo&reg;;",
"     </li>",
"     <li>",
"      Phoslyra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PhosLo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1002723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Salt",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1002747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39685?source=see_link\">",
"      see \"Calcium acetate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of hyperphosphatemia in end-stage renal failure:",
"     </b>",
"     Oral: Adults: Dose expressed in mg of",
"     <b>",
"      calcium acetate",
"     </b>",
"     (PhosLo&reg;): 1334 mg (two 667 mg capsules) with each meal; may increase up to 2668 mg (four 667 mg capsules) with each meal; can be increased gradually to bring the serum phosphate value &lt;6 mg/dL as long as hypercalcemia does not develop (usual dose: 2001-2668 mg calcium acetate with each meal); do not give additional calcium supplements",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gelcap, oral: 667 mg [equivalent to elemental calcium 169 mg (8.45 mEq)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PhosLo&reg;: 667 mg [equivalent to elemental calcium 169 mg (8.45 mEq)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phoslyra&trade;: 667 mg/5 mL (473 mL) [contains maltitol (1 g/5 mL), propylene glycol; black cherry-menthol flavor; equivalent to elemental calcium 169 mg (8.45 mEq)/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eliphos&trade;: 667 mg [equivalent to elemental calcium 169 mg (8.45 mEq)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Gelcap",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1002753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with plenty of fluids with meals to optimize effectiveness",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1002724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of  hyperphosphatemia in end-stage renal failure (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F144331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       PhosLo&reg; may be confused with Phos-Flur&reg;, ProSom",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F144329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercalcemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal:  Diarrhea (oral solution), nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Dizziness, edema, pruritus, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1002726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to calcium formulation; hypercalcemia, renal calculi, ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3429126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with sarcoidosis, respiratory failure, acidosis, renal or cardiac disease, and in patients who may be at risk of cardiac arrhythmias, including digitalized patients. Hypercalcemia and hypercalciuria are most likely to occur in hypoparathyroid patients receiving high doses of vitamin D. Calcium administration interferes with absorption of some minerals and drugs; use with caution. Some products may contain aspartame which is metabolized to phenylalanine and must be avoided in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1002727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple salt forms of calcium exist; close attention must be paid to the salt form when ordering and administering calcium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or under-dosing. Some products may contain tartrazine which may cause allergic reactions in susceptible individuals. Avoid use of calcium-containing phosphate binders (calcium acetate or phosphate) in dialysis patients with hypercalcemia or whose plasma PTH concentrations are &lt;150 pg/mL on two consecutive measurements. Mild to severe hypercalcemia may occur; decrease calcium acetate dose or temporarily discontinue, depending on severity of hypercalcemia; in addition, decrease or discontinue any concomitant vitamin D therapy. Chronic hypercalcemia may result in vascular calcification and other soft tissue calcification.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CefTRIAXone: Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate.  Management: Use of ceftriaxone with calcium-containing solutions within 48 hours of one another is contraindicated in neonates (28 days of age or younger).  In older patients, flush lines with compatible fluid between administration.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Calcium Salts may decrease the absorption of Estramustine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moxifloxacin (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3429127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not give orally with bran, foods high in oxalates (spinach, sweet potatoes, rhubarb, beans), or phytic acid (unleavened bread, raw beans, seeds, nuts, grains, soy isolates) which may decrease calcium absorption; minimize administration with dairy products (when treating deficiency state) as this will reduce absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F144289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12769413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Calcium crosses the placenta. The amount of calcium reaching the fetus is determined by maternal physiological changes. Intestinal absorption of calcium increases during pregnancy. If use is required in pregnant patients with end stage renal disease, fetal harm is not expected if maternal calcium concentrations are monitored and maintained within normal limits as recommended (IOM, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1002755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum calcium (twice weekly during initial dose adjustments), serum phosphorus; serum calcium-phosphorus product; intact parathyroid hormone (iPTH)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1002742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Calcium: Serum calcium: 8.5-10.5 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 7-12 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0-2 years: 8.8-11.2 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum phosphorus:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stage 3 and 4 CKD: &ge;2.7 to &lt;4.6 mg/dL (adults); within age-appropriate limits (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stage 5 CKD: 3.5-5.5 mg/dL (children &gt;12 years and adults); 4-6 mg/dL (children 1-12 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum calcium-phosphorus product: Stage 3-5 CKD: &lt;55 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     (children &gt;12 years and adults); &lt;65 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     (children &le;12 years)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1002741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium moderates nerve and muscle performance via action potential excitation threshold regulation; it is necessary for maintaining the functional integrity of nervous, muscular, and skeletal systems and cell-membrane and capillary permeability. Calcium acetate combines with dietary phosphate to form insoluble calcium phosphate which is excreted in feces and reduces phosphate absorption.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1002743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: 25% to 35%; varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, young adults 25%); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Primarily in the feces as unabsorbed calcium",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13205444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/38/7780?source=see_link\">",
"      see \"Calcium acetate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with meals; avoid alcohol. May cause constipation or dry mouth. Report severe, unresolved GI disturbances.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1002758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 g calcium acetate = 250 mg elemental calcium = 12.7 mEq calcium.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Calcium Content of Calcium Salts",
"     </caption>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/1 g of salt form)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mEq/g)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Approximate Equivalent Doses",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg of calcium salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium acetate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12.7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         354",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium carbonate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         225",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium chloride",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         270",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         330",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium citrate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         211",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         425",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium glubionate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         64",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1400",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         90",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium lactate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         130",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         700",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium phosphate (tribasic)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         390",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         19.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         233",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Dietary Reference Intakes for Calcium and Vitamin D",
"      </i>",
"      , Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Ross AC, Taylor CL, et al, eds, Washington, DC: National Academies Press (US), 2011. Available at",
"      <a href=\"file://www.nap.edu/catalog.php?record_id=13050\" target=\"_blank\">",
"       file://www.nap.edu/catalog.php?record_id=13050",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21301/abstract-text/21796828/pubmed\" id=\"21796828\" target=\"_blank\">",
"        21796828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13085 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_51_21301=[""].join("\n");
var outline_f20_51_21301=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144308\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663225\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002723\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002747\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144293\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144278\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002753\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002724\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144331\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144329\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002726\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429126\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002727\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298930\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144287\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429127\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144289\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12769413\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002755\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002742\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002741\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002743\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13205444\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002758\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13085\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13085|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39685?source=related_link\">",
"      Calcium acetate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/38/7780?source=related_link\">",
"      Calcium acetate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_51_21302="Nitroprusside: Drug information";
var content_f20_51_21302=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nitroprusside: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/36/34371?source=see_link\">",
"    see \"Nitroprusside: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/52/40773?source=see_link\">",
"    see \"Nitroprusside: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nitropress&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12817125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nipride&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F202230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vasodilator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F202200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute hypertension:",
"     </b>",
"     I.V.: Initial: 0.25-0.3 mcg/kg/minute; may be titrated by 0.5 mcg/kg/minute every few minutes to achieve desired hemodynamic effect (JNC 7; Rhoney, 2009); usual dose: 3 mcg/kg/minute; maximum dose: 10 mcg/kg/minute. When administered in doses &gt;3 mcg/kg/minute for prolonged periods of time (eg, 3-4 days), thiocyanate levels should be monitored daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute decompensated heart failure:",
"     </b>",
"     I.V.: Initial: 5-10",
"     <b>",
"      mcg/minute",
"     </b>",
"     ; may be titrated rapidly (eg, up to every 5 minutes) to achieve desired hemodynamic effect; usual dosage range: 5-300",
"     <b>",
"      mcg/minute",
"     </b>",
"     . Doses &gt;400",
"     <b>",
"      mcg/minute",
"     </b>",
"     are not recommended due to minimal added benefit and increased risk for thiocyanate toxicity (HFSA, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F202218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/52/40773?source=see_link\">",
"      see \"Nitroprusside: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Acute hypertension:",
"     </b>",
"     I.V.: Initial: 0.3-0.5 mcg/kg/minute; may be titrated every few minutes to achieve desired hemodynamic effect; maximum dose: 10 mcg/kg/minute (Hegenbarth, 2008; NHBPEP, 2005). Doses &ge;1.8 mcg/kg/minute are associated with increased cyanide concentration in pediatric patients (Moffett, 2008); monitor cyanide levels with prolonged use (eg, &gt;72 hours) (NHBPEP, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F202201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F202202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling.  However, use in patients with renal impairment may lead to the accumulation of thiocyanate and subsequent toxicity; limit use.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F202203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling; due to the risk of cyanide toxicity, use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F202177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nitropress&reg;: 25 mg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F202162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F202182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. infusion only; infusion pump required; must be diluted prior to administration; not for direct injection. Due to potential for excessive hypotension, continuously monitor patient&rsquo;s blood pressure during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14473001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     50 mg in 250 mL (concentration: 200",
"     <b>",
"      mcg",
"     </b>",
"     /mL)",
"     <b>",
"      or",
"     </b>",
"     100 mg in 250 mL (concentration: 400",
"     <b>",
"      mcg",
"     </b>",
"     /mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14473002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     100",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"     <b>",
"      or",
"     </b>",
"     200",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F202236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W (preferred), LR, NS;",
"     <b>",
"      Note:",
"     </b>",
"     Exposure to light causes decompensation regardless of the diluent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alprostadil, argatroban, atracurium, bivalirudin, caffeine citrate, calcium chloride, calcium gluconate, dexmedetomidine, diltiazem, dobutamine, dobutamine with dopamine, dobutamine with lidocaine, dobutamine with nitroglycerin, dopamine, dopamine with lidocaine, dopamine with nitroglycerin, enalaprilat, epinephrine, esmolol, famotidine, furosemide, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;),  inamrinone, indomethacin, insulin (regular), isoproterenol, labetalol, lidocaine, lidocaine with nitroglycerin, magnesium sulfate, micafungin, midazolam, milrinone, morphine, nesiritide, norepinephrine, nitroglycerin, pancuronium, potassium chloride, potassium phosphate, procainamide, propofol, tacrolimus, theophylline, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Drotrecogin alfa, levofloxacin, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amiodarone, cisatracurium, haloperidol, metoprolol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, heparin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F202181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hypertensive crises; acute decompensated heart failure (HF); used for controlled hypotension to reduce bleeding during surgery",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F202238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nitroprusside may be confused with nitroglycerin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F202228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, ECG changes, flushing, hypotension (excessive), palpitation, substernal distress, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Apprehension, dizziness, headache, intracranial pressure increased, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Metabolic acidosis (secondary to cyanide toxicity), hypothyroidism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, ileus, nausea, retching, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Methemoglobinemia, platelet aggregation decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyperreflexia (secondary to thiocyanate toxicity), muscle twitching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Miosis (secondary to thiocyanate toxicity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus (secondary to thiocyanate toxicity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Hyperoxemia (secondary to cyanide toxicity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Cyanide toxicity, diaphoresis, thiocyanate toxicity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F202185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of compensatory hypertension (aortic coarctation, arteriovenous shunting); to produce controlled hypotension during surgery in patients with known inadequate cerebral circulation or in moribund patients requiring emergency surgery; high output heart failure associated with reduced systemic vascular resistance (eg, septic shock); congenital optic atrophy or tobacco amblyopia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F202166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cyanide toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Except when used briefly or at low (&lt;2 mcg/kg/minute) infusion rates, nitroprusside gives rise to large cyanide quantities. Do not use the maximum dose for more than 10 minutes; if blood pressure is not controlled by the maximum rate after 10 minutes, discontinue infusion. Monitor for cyanide toxicity via acid-base balance and venous oxygen concentration; however, clinicians should note that these indicators may not always reliably indicate cyanide toxicity.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension:",
"     <b>",
"      [U.S. Boxed Warning]: Excessive hypotension resulting in compromised perfusion of vital organs may occur; continuous blood pressure monitoring by experienced personnel is required.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thiocyanate toxicity: Can occur in patients with renal impairment or those on prolonged infusions (ie, &gt;3 mcg/kg/minute for &gt;72 hours).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia: When nitroprusside is used for controlled hypotension during surgery, correct pre-existing anemia prior to use when possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intracranial pressure: Use with extreme caution in patients with elevated intracranial pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with extreme caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypovolemia: When nitroprusside is used for controlled hypotension during surgery, correct pre-existing hypovolemia prior to use when possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with extreme caution in patients with renal impairment; use the lowest end of the dosage range; monitor thiocyanate concentrations closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration:",
"     <b>",
"      [U.S. Boxed Warning]: Solution must be further diluted with 5% dextrose in water. Do not administer by direct injection.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F202171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F202173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13263869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have shown that nitroprusside may cross the placental barrier and result in fetal cyanide levels that are dose-related to maternal nitroprusside levels.  However, information related to use in pregnancy is limited.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F202206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nitropress Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/mL (2 mL): $57.29",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F202175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate; monitor for cyanide and thiocyanate toxicity; monitor acid-base status as acidosis can be the earliest sign of cyanide toxicity; monitor thiocyanate levels if requiring prolonged infusion (&gt;3 days) or dose &gt;3 mcg/kg/minute or patient has renal dysfunction; monitor cyanide blood levels in patients with decreased hepatic function; cardiac monitor and blood pressure monitor required",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F202178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum thiocyanate levels are not helpful in detecting toxicity. A level may be confirmatory if a patient is exhibiting signs and symptoms of thiocyanate toxicity. Initial signs of toxicity (eg, tinnitus) may be observed at levels &gt;35 mcg/mL (manufacturer suggests 60 mcg/mL), but serious toxicity typically may not occur with levels &lt;100 mcg/mL.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F202187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Doketrol (AR);",
"     </li>",
"     <li>",
"      Ketostix (AU);",
"     </li>",
"     <li>",
"      Naniprus (PL);",
"     </li>",
"     <li>",
"      Nipride (BE, CH, FR, GB, IE, LU, NL);",
"     </li>",
"     <li>",
"      Niprusodio (UY);",
"     </li>",
"     <li>",
"      Nipruss (DE, LU);",
"     </li>",
"     <li>",
"      Nitan (MX);",
"     </li>",
"     <li>",
"      Nitriate (FR);",
"     </li>",
"     <li>",
"      Nitropresabbott (BR);",
"     </li>",
"     <li>",
"      Nitroprusiato de sodio (PE, PY, VE);",
"     </li>",
"     <li>",
"      Nitroprusiato de sodio-ecar (CO);",
"     </li>",
"     <li>",
"      Nitroprussiat Fides (ES);",
"     </li>",
"     <li>",
"      Sodio Nitroprussiato (IT);",
"     </li>",
"     <li>",
"      Sodium Nitroprusside (GB);",
"     </li>",
"     <li>",
"      Sodium Nitroprusside BP (AU);",
"     </li>",
"     <li>",
"      Sonide (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F202165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes peripheral vasodilation by direct action on venous and arteriolar smooth muscle, thus reducing peripheral resistance; will increase cardiac output by decreasing afterload; reduces aortal and left ventricular impedance",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F202184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Hypotensive effect: &lt;2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Hypotensive effect: 1-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Nitroprusside combines with hemoglobin to produce cyanide and cyanmethemoglobin. Cyanide detoxification occurs via rhodanase-mediated conversion of cyanide to thiocyanate; rhodanase couples cyanide molecules to sulfane sulfur groups from a sulfur donor (eg, thiosulfate, cystine, cysteine). This process has limited capacity and may become overwhelmed with large exposures once sulfur donor supplies are exhausted resulting in toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Nitroprusside, circulatory: ~2 minutes; Thiocyanate, elimination: ~3 days (may be doubled or tripled in renal failure)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as thiocyanate)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berlin CM, &ldquo;The Treatment of Cyanide Poisoning in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1970, 46(5):793-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21302/abstract-text/4320419/pubmed\" id=\"4320419\" target=\"_blank\">",
"        4320419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broderick J, Connolly S, Feldmann E, et al, &ldquo;Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2007, 38(6):2001-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21302/abstract-text/17478736/pubmed\" id=\"17478736\" target=\"_blank\">",
"        17478736",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erstad BL and Barletta JF, &ldquo;Treatment of Hypertension in the Perioperative Patient,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(1):66-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21302/abstract-text/10669188/pubmed\" id=\"10669188\" target=\"_blank\">",
"        10669188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21302/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ihlen H, Myhre E, and Opstad P, &ldquo;Evaluation of Potential Adverse Effects of Sodium Nitroprusside During Pacing-Induced Myocardial Ischaemia in Man,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 1984, 5(10):834-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21302/abstract-text/6499856/pubmed\" id=\"6499856\" target=\"_blank\">",
"        6499856",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21302/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moffett BS and Price JF, \"Evaluation of Sodium Nitroprusside Toxicity in Pediatric Cardiac Surgical Patients,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(11):1600-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21302/abstract-text/18957627/pubmed\" id=\"18957627\" target=\"_blank\">",
"        18957627",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21302/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palmer RF and Lasseter KC, &ldquo;Drug Therapy: Sodium Nitroprusside,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1975, 292(6):294-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21302/abstract-text/1089194/pubmed\" id=\"1089194\" target=\"_blank\">",
"        1089194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21302/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rhoney D and Peacock WF, &ldquo;Intravenous Therapy for Hypertensive Emergencies, Part 1&rdquo;,",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2009, 66(15):1343-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21302/abstract-text/19635770/pubmed\" id=\"19635770\" target=\"_blank\">",
"        19635770",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vesey CJ and Cole PV, &ldquo;Blood Cyanide and Thiocyanate Concentrations Produced by Long-Term Therapy With Sodium Nitroprusside,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1985, 57(2):148-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21302/abstract-text/3970795/pubmed\" id=\"3970795\" target=\"_blank\">",
"        3970795",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wesson DE, Foley R, Sabatini S, et al, &ldquo;Treatment of Acute Cyanide Intoxication With Hemodialysis,&rdquo;",
"      <i>",
"       Am J Nephrol",
"      </i>",
"      , 1985, 5(2):121-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21302/abstract-text/3993700/pubmed\" id=\"3993700\" target=\"_blank\">",
"        3993700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9707 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-EA571C30FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_51_21302=[""].join("\n");
var outline_f20_51_21302=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709173\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202198\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12817125\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202230\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202200\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202218\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202201\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202202\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202203\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202177\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202162\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202182\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473001\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473002\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202236\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202181\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202238\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202228\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202185\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202166\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299769\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202171\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202173\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13263869\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202206\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323524\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202175\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202178\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202187\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202165\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202184\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9707\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9707|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/36/34371?source=related_link\">",
"      Nitroprusside: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/52/40773?source=related_link\">",
"      Nitroprusside: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_51_21303="Infliximab: Pediatric drug information";
var content_f20_51_21303=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Infliximab: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"    see \"Infliximab: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/23/2422?source=see_link\">",
"    see \"Infliximab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F182756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Remicade&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F182757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Remicade&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antirheumatic, Disease Modifying",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Immunosuppressant Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Monoclonal Antibody",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Tumor Necrosis Factor (TNF) Blocking Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"      see \"Infliximab: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. infusion:",
"     <b>",
"      Note:",
"     </b>",
"     Premedication with antihistamines (H",
"     <sub>",
"      1",
"     </sub>",
"     -antagonist and/or H",
"     <sub>",
"      2",
"     </sub>",
"     -antagonist), acetaminophen and/or corticosteroids may be considered to prevent and/or manage infusion-related reactions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Crohn's disease: Initial: 5 mg/kg; repeat 5 mg/kg/dose at 2 and 6 weeks after the first infusion; maintenance: 5 mg/kg/dose every 8 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     If the response is incomplete, dose has been increased up to 10 mg/kg (Stephens, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Juvenile idiopathic arthritis uncontrolled by conventional disease modifying drugs (in combination with methotrexate): Initial: 3 mg/kg; repeat 3 mg/kg/dose at 2 and 6 weeks after the first infusion, then 3-6 mg/kg/dose every 8 weeks thereafter (Ruperto, 2009). Alternatively, some studies used 6 mg/kg/dose starting at week 14 of methotrexate therapy; repeat 6 mg/kg/dose 2 and 6 weeks after the first infusion, then every 8 weeks thereafter (Ruperto, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Crohn's disease or fistulizing disease: Initial: 5 mg/kg; repeat 5 mg/kg/dose at 2 and 6 weeks after the first infusion; maintenance: 5 mg/kg/dose every 8 weeks. If response is incomplete, may increase dose up to 10 mg/kg. Patients who do not respond by week 14 are unlikely to respond with continued infliximab dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rheumatoid arthritis (in combination with methotrexate): Initial: 3 mg/kg; repeat 3 mg/kg/dose at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. If the response is incomplete, may increase dose up to 10 mg/kg or treat as often as every 4 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ankylosing spondylitis: Initial: 5 mg/kg; repeat 5 mg/kg/dose at 2 and 6 weeks after the first infusion, then every 6 weeks thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plaque psoriasis: 5 mg/kg at 0, 2, and 6 weeks, then every 8 weeks thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Psoriatic arthritis: Initial: 5 mg/kg; repeat 5 mg/kg/dose at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ulcerative colitis: Initial: 5 mg/kg; repeat 5 mg/kg/dose at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F182738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Remicade&reg;: 100 mg [contains polysorbate 80, sucrose 500 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F182723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at file://www.remicade.com/remicade/assets/Med_Guide.pdf, must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Administer by I.V. infusion over 2-3 hours at a final concentration between 0.4-4 mg/mL in NS. A rate titration schedule may be used to prevent acute infusion reactions. For a total 250 mL volume to be infused, initiate at a rate of 10 mL/hour for first 15 minutes followed by 20 mL/hour for 15 minutes, 40 mL/hour for 15 minutes, 80 mL/hour for 15 minutes, 150 mL/hour for 30 minutes, and then 250 mL/hour until infusion is complete. Administer through an in-line, sterile, nonpyrogenic, low-protein-binding filter with pore size of &le;1.2 micrometers; do not infuse in the same I.V. line as other agents",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F182791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS; do not infuse with other agents.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store vial in refrigerator; do not freeze; infliximab solution should be used immediately after reconstitution since the vial contains no preservative; do not shake or agitate vigorously; do not use if discolored or cloudy; the reconstituted dose must be further diluted in NS and the infusion should begin within 3 hours of preparation",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction of signs and symptoms of Crohn's disease in patients with moderate to severely active disease who have had an inadequate response to conventional therapy (FDA approved in children &ge;6 years and adults); reduction in the number of draining enterocutaneous fistulas in patients with fistulizing Crohn's disease (FDA approved in adults); treatment of refractory ulcerative colitis (FDA approved in adults); in combination with methotrexate for reducing signs and symptoms, inhibiting progression of structural damage, and improving physical function in patients with moderate to severe rheumatoid arthritis (FDA approved in adults); reduction of signs and symptoms of ankylosing spondylitis (FDA approved in adults); treatment of psoriatic arthritis (to reduce signs/symptoms of active arthritis and inhibit progression of structural damage and improve physical function); treatment of chronic severe plaque psoriasis (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F182793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       InFLIXimab may be confused with riTUXimab",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Remicade&reg; may be confused with Renacidin&reg;, Rituxan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F182789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, fever, headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased (risk increased with concomitant methotrexate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, dyspnea, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anti-infliximab antibodies (variable; Mayer, 2006), development of antibodies to double-stranded DNA, development of antinuclear antibodies, development of new abscess (Crohn's patients with fistulizing disease), infection, infusion reactions, moniliasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abscess, adult respiratory distress syndrome, agranulocytosis, allergic reaction, anaphylactic reactions/shock, anemia, angina, angioedema, arrhythmia, autoimmune hepatitis, basal cell carcinoma, biliary pain, bradycardia, brain infarction, breast cancer, bronchospasm, cardiac arrest, cellulitis, cholecystitis, cholelithiasis, cholestasis, circulatory failure, confusion, constipation, dehydration, delayed hypersensitivity (plaque psoriasis), demyelinating disorders (eg, multiple sclerosis, optic neuritis); diaphoresis increased, dizziness, drug-induced lupus-like syndrome, edema, erythema multiforme, gastrointestinal hemorrhage, Guillain-Barr&eacute; syndrome, heart failure, hemolytic anemia, hepatic carcinoma, hepatitis, hepatitis B reactivation, hepatocellular damage, hepatosplenic T-cell lymphoma (HSTCL), Hodgkin's disease, hypersensitivity reactions, hypotension, ileus, interstitial fibrosis, interstitial pneumonitis, intervertebral disk herniation, intestinal obstruction, intestinal perforation, intestinal stenosis, jaundice, laryngeal/pharyngeal edema, latent tuberculosis reactivation, leiomyosarcoma, leukemias, leukopenia, liver failure, liver function tests increased, lupus-like syndrome, lymphadenopathy, lymphomas, malignancies, melanoma, meningitis, menstrual irregularity, MI, myalgia, neuritis, neuropathy, numbness, opportunistic infection, pancreatitis, pancytopenia, pericardial effusion, peripheral neuropathy, peritonitis pleural effusion, pleurisy, pneumonia, proctalgia, psoriasis (including new onset, palmoplantar, pustular, or exacerbation), pulmonary edema, pulmonary embolism, renal calculus, renal cell carcinoma, renal failure, respiratory insufficiency, sarcoidosis, seizure, sepsis, serum sickness, Stevens-Johnson syndrome, suicide attempt, syncope, tachycardia, taste abnormal, tendon disorder, thrombocytopenia, thrombophlebitis (deep), tingling, toxic epidermal necrolysis, ulceration, urticaria, vasculitis (systemic and cutaneous), worsening CHF",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to infliximab, murine proteins, or any component; patients with moderate or severe (NYHA class III/IV) congestive heart failure. Infliximab doses &gt;5 mg/kg should not be administered to patients with moderate to severe heart failure; doses at 10 mg/kg have been associated with an increased incidence of death and hospitalization due to  worsening heart failure.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with a history of recurrent infections or illnesses which predispose the patient to infection. Positive antinuclear antibody titers have been detected in patients (with negative baselines). Rare cases of autoimmune disorder, including lupus-like syndrome, have been reported; monitor and discontinue if symptoms develop; if antibodies to double-stranded DNA are confirmed in a patient with lupus-like symptoms, infliximab should be discontinued. Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients receiving infliximab are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate or corticosteroids) and may present as disseminated (rather than local) disease. Active tuberculosis (or reactivation of latent tuberculosis), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral, or other opportunistic infections have been reported in patients receiving TNF-blocking agents, including infliximab",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Monitor closely for signs/symptoms of infection; discontinue for serious infection or sepsis. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infection and develop severe systemic illness. Other opportunistic infections (eg, invasive fungal infections, listeriosis,",
"     <i>",
"      Pneumocystis",
"     </i>",
"     ) have occurred during therapy. Caution should be exercised when considering use in patients with conditions that predispose them to infections (eg, diabetes) or residence/travel from areas of endemic mycoses (blastomycosis, coccidioidomycosis, histoplasmosis), or with latent or localized infections. Do not give with clinically important active infection. Patients who develop a new infection while undergoing treatment should be monitored closely. Serious infections were reported when used in combination with anakinra or etanercept; combination of infliximab and anakinra is not recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Reactivation of latent tuberculosis infections and active tuberculosis (may be disseminated or extrapulmonary) have been associated with infliximab therapy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Tuberculosis (disseminated or extrapulmonary) has been reactivated in patients previously exposed to tuberculosis while on therapy. Most cases of reactivation have been reported within the first 3-6 months of treatment. Patients should be evaluated for tuberculosis risk factors and latent tuberculosis infection with a tuberculin skin test prior and during therapy; patients with initial negative tuberculin skin tests should receive continued monitoring for tuberculosis throughout treatment. Caution should be exercised when considering the use of infliximab in patients who have been exposed to tuberculosis. Treatment of latent tuberculosis should be initiated before therapy is used. The risk/benefit ratio should be weighed in patients who have resided in regions where histoplasmosis is endemic; infliximab has been associated with reactivation of hepatitis B in patients who are chronic carriers of this virus; patients who develop a new infection while receiving infliximab should be monitored closely; if a patient develops a serious infection while on treatment, infliximab therapy should be discontinued. Rare reactivation of hepatitis B virus (HBV) has occurred in chronic virus carriers; use with caution; evaluate prior to initiation and during treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hepatosplenic T-cell lymphoma has been reported in patients with Crohn&rsquo;s disease or ulcerative colitis treated with infliximab and concurrent or prior azathioprine or mercaptopurine use, usually reported in adolescent and young adult males",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Infliximab use has been associated with reports of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal). Use with caution in patients with a history of significant hematologic abnormalities; discontinue therapy if significant hematologic abnormalities develop.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In children and adolescents, lymphomas and other malignancies, some fatal, have been reported with use of TNF blockers",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Use may affect defenses against malignancies; impact on the development and course of malignancies is not fully defined. In an analysis of children and adolescents who had received TNF blockers (etanercept and infliximab), the FDA identified 48 cases of malignancy. Of the 48 cases, ~50% were lymphomas (eg, Hodgkin's and non-Hodgkin's lymphoma). Other malignancies, such as leukemia, melanoma, and solid organ tumors, were reported; malignancies rarely seen in children (eg, leiomyosarcoma, hepatic malignancies, and renal cell carcinoma) were also observed. Of note, most of these cases (88%) were receiving other immunosuppressive medications (eg, azathioprine and methotrexate). A higher incidence of nonmelanoma skin cancers was noted in adalimumab-treated patients (0.9/100 patient years), when compared to the control group (0.3/100 patient years). As compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis has been previously associated with an increased rate of lymphoma. The role of TNF blockers in the development of malignancies in children cannot be excluded. The FDA also reviewed 147 postmarketing reports of leukemia (including acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia) in patients (children and adults) using TNF blockers. Average onset time to development of leukemia was within the first 1-2 years of TNF blocker initiation. Although most patients were receiving other immunosuppressive agents, the role of TNF blockers in the development of leukemia could not be excluded. The FDA concluded that there is a possible association with the development of leukemia and the use of TNF blockers. Patients should be monitored closely for signs and symptoms suggestive of malignancy, evidence of which should result in prompt discontinuation of the medication and appropriate diagnostic evaluation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May also cause new-onset psoriasis. Analysis by the FDA identified 69 cases of new-onset psoriasis (including pustular, palmoplantar) occurring in patients using TNF blockers for the treatment of conditions other than psoriasis and psoriatic arthritis. Of the 69 cases, two were reported in children and 12 required hospitalization, the most severe outcome. Improvement was seen when the TNF blocker was discontinued. The FDA concluded that there is a possible association with new-onset psoriasis and the use of TNF blockers. Patients should be monitored closely for signs and symptoms suggestive of new-onset psoriasis, evidence of which should result in prompt discontinuation of the medication and appropriate diagnostic evaluation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Acute infusion reactions may occur. Hypersensitivity reaction may occur within 2 hours of infusion. Medication and equipment for management of hypersensitivity reaction should be available for immediate use. Interruptions and/or reinstitution at a slower rate may be required. Pretreatment may be considered, and may be warranted in all patients with prior infusion reactions. Serum sickness-like reactions have occurred; possibly associated with a decreased response to treatment. The development of antibodies to infliximab may increase the risk of hypersensitivity and/or infusion reactions; concomitant use of immunosuppressants may lessen the development of anti-infliximab antibodies. The risk of infusion reactions may be increased with retreatment after an interruption or discontinuation of prior maintenance therapy. Retreatment in psoriasis patients should be resumed as a scheduled maintenance regimen without any induction doses; use of an induction regimen should be used cautiously for retreatment of all other patients.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Rare cases of CNS demyelinating disorders, such as multiple sclerosis, optic neuritis, Guillain-Barr&eacute; syndrome, and seizure disorders have been reported in patients undergoing infliximab therapy; consider discontinuing therapy in patients who develop significant CNS adverse reactions. Severe hepatic reactions (some fatal), including acute liver failure, hepatitis, and cholestasis have occurred between 2 weeks to more than a year after infliximab initiation. Severe hepatic reactions (including hepatitis, jaundice, acute hepatic failure, and cholestasis) have been reported during treatment; discontinue infliximab if jaundice and/or liver enzyme elevation (&ge;5 times the upper limit of normal) develops. Higher incidence of mortality and hospitalization for worsening heart failure have been reported in patients with CHF treated with infliximab, especially those patients treated at a higher dose of 10 mg/kg; do not initiate infliximab therapy in patients with moderate or severe CHF.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. Infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F182732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F182734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F182745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Infliximab crosses the placenta and can be detected in the serum of infants for up to 6 months following",
"     <i>",
"      in utero",
"     </i>",
"     exposure. The safety of administering live or live-attenuated vaccines to exposed infants is not known.  A Rheumatoid Arthritis and Pregnancy Registry has been established for women exposed to infliximab during pregnancy (Organization of Teratology Information Services, 877-311-8972).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinalysis, blood chemistry, ESR, blood pressure, signs of infection, CBC; tuberculin skin test prior to initiation of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Crohn's disease: C-reactive protein, frequency of stools, abdominal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rheumatoid arthritis: C-reactive protein, rheumatoid factor, decrease in pain, swollen joints, stiffness",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chimeric monoclonal antibody which binds specifically to human tumor necrosis factor alpha (TNF&alpha;); inhibits binding of TNF&alpha; with its receptors",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1047896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Crohn's disease: 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rheumatoid arthritis: 3-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Crohn's disease: 8-48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rheumatoid arthritis: 6-12 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Within the vascular compartment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 3 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal: 8-9.5 days",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/23/2422?source=see_link\">",
"      see \"Infliximab: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if persistent fever, bruising, cough, flu-like symptoms, severe fatigue, jaundice, abdominal pain, bleeding, pallor, shortness of breath, swelling of ankles or feet, vision change, weakness in arms and/or legs, numbness, or chest discomfort occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1047899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A retrospective study of 57 children receiving 361 infliximab infusions reported that the rate of infusion-related reactions in children was similar to that in adults (9.7% incidence shown). Female gender, immunosuppressive use for &lt;4 months, and prior infusion reactions were risk factors for subsequent infusion reactions in children (Crandall, 2003)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Crandall WV and Mackner LM, &ldquo;Infusion Reactions to Infliximab in Children and Adolescents: Frequency, Outcome and a Predictive Model,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2003, 17(1):75-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21303/abstract-text/12492735/pubmed\" id=\"12492735\" target=\"_blank\">",
"        12492735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hyams JS, &ldquo;Use of Infliximab in the Treatment of Crohn's Disease in Children and Adolescents,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2001, 33 (Suppl 1):S36-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21303/abstract-text/11685974 /pubmed\" id=\"11685974 \" target=\"_blank\">",
"        11685974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hyams JS, Markowitz J, and Wyllie R, &ldquo;Use of Infliximab in the Treatment of Crohn's Disease in Children and Adolescents,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2000, 137(2):192-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21303/abstract-text/10931411/pubmed\" id=\"10931411\" target=\"_blank\">",
"        10931411",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayer L and Young Y, \"Infusion Reactions and Their Management,\"",
"      <i>",
"       Gastroenterol Clin North Am",
"      </i>",
"      , 2006, 35(4):857-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21303/abstract-text/17129817/pubmed\" id=\"17129817\" target=\"_blank\">",
"        17129817",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ruperto N, Lovell DJ, Cuttica R, et al, \"A Randomized, Placebo-Controlled Trial of Infliximab Plus Methotrexate for the Treatment of Polyarticular-Course Juvenile Rheumatoid Arthritis,\"",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2007, 56(9):3096-106.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21303/abstract-text/17763439/pubmed\" id=\"17763439\" target=\"_blank\">",
"        17763439",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ruperto N, Lovell DJ, Cuttica R, et al, \"Long-Term Efficacy and Safety of Infliximab Plus Methotrexate for the Treatment of Polyarticular Course Juvenile Rheumatoid Arthritis: Findings From an Open-Label Treatment Extension,\"",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2009 [Epub ahead of print].",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21303/abstract-text/19406734 /pubmed\" id=\"19406734 \" target=\"_blank\">",
"        19406734",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al, &ldquo;Use of Infliximab in Pediatric Patients With Inflammatory Bowel Disease,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2001, 35(7-8):823-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21303/abstract-text/11485127/pubmed\" id=\"11485127\" target=\"_blank\">",
"        11485127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stephens MC, Shepanski MA, Mamula P, et al, &ldquo;Safety and Steroid-Sparing Experience Using Infliximab for Crohn's Disease at a Pediatric Inflammatory Bowel Disease Center,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2003, 98(1):104-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21303/abstract-text/12526944/pubmed\" id=\"12526944\" target=\"_blank\">",
"        12526944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilkinson N, Jackson G, and Gardner-Medwin J, &ldquo;Biologic Therapies for Juvenile Arthritis,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2003, 88(3):186-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21303/abstract-text/12598373 /pubmed\" id=\"12598373 \" target=\"_blank\">",
"        12598373",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13381 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-57354D163F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_51_21303=[""].join("\n");
var outline_f20_51_21303=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708921\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182756\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182757\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047891\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047884\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182738\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182723\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874621\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047894\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182791\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047887\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047893\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182793\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182789\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047898\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047883\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047882\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299517\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182732\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182734\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182745\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047890\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047881\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047896\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047897\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047889\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047899\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13381\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13381|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=related_link\">",
"      Infliximab: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/23/2422?source=related_link\">",
"      Infliximab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_51_21304="Focal RFA Barretts";
var content_f20_51_21304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    Schematic illustration of primary circumferential and secondary focal radiofrequency ablation (RFA) of Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 580px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     (A)",
"    </strong>",
"    Pre-treatment image of a Barrett's segment.",
"    <br>",
"     <strong>",
"      (B, C)",
"     </strong>",
"     The esophageal diameter is measured at 1-cm intervals with a sizing balloon placed over a guidewire.",
"     <br>",
"      <strong>",
"       (D)",
"      </strong>",
"      Introduction of the RFA balloon catheter over the guidewire.",
"      <br>",
"       <strong>",
"        (E)",
"       </strong>",
"       The inflated RFA balloon positioned 1 cm above the top of the Barrett's segment.",
"       <br>",
"        <strong>",
"         (F)",
"        </strong>",
"        The RFA balloon repositioned for ablation of the second zone after ablation of the first zone with an overlap of 1 cm with the first ablation zone.",
"        <br>",
"         <strong>",
"          (G)",
"         </strong>",
"         Image of the treated Barrett's segment immediately after the RFA ablation with visible necrosis of the superficial mucosa.",
"         <br>",
"          <strong>",
"           (H)",
"          </strong>",
"          Image of the healed distal esophagus three months after RFA treatment with regeneration with neosquamous mucosa and three small islands of residual Barrett's mucosa.",
"          <br>",
"           <strong>",
"            (I)",
"           </strong>",
"           Introduction of the endoscope with the HALO90 cap for focal ablation.",
"           <br>",
"            <strong>",
"             (J)",
"            </strong>",
"            Ablation of the third island of Barrett's mucosa. The necrosis caused by ablation of the first two islands is visible proximally.",
"            <br>",
"             <strong>",
"              (K)",
"             </strong>",
"             Image of the distal esophagus immediately after ablation of the three residual islands of Barrett's mucosa.",
"             <br>",
"              <strong>",
"               (L)",
"              </strong>",
"              Image of the healed distal esophagus, showing complete regeneration with neosquamous mucosa.",
"              <div class=\"footnotes\">",
"              </div>",
"              <div class=\"reference\">",
"               Reproduced with permission of www.endosurgery.eu. Copyright &copy; 2010 Esophageal Research Foundation Amsterdam.",
"              </div>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_51_21304=[""].join("\n");
var outline_f20_51_21304=null;
var title_f20_51_21305="Cisplatin: Drug information";
var content_f20_51_21305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cisplatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/20/14661?source=see_link\">",
"    see \"Cisplatin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/8/34949?source=see_link\">",
"    see \"Cisplatin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F151928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Platinum Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F151883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      VERIFY ANY CISPLATIN DOSE EXCEEDING 100 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      PER COURSE.",
"     </b>",
"     Pretreatment hydration with 1-2 L of I.V. fluid is recommended. Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bladder cancer, advanced:",
"     </b>",
"     I.V.: 50-70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3-4 weeks; heavily pretreated patients: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer, metastatic:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Single agent: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Combination therapy: 75-100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 weeks or (unlabeled dosing) 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (Ozols, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Testicular cancer, metastatic:",
"     </b>",
"     I.V.: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days repeated every 3 weeks (Cushing, 2004; Saxman, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cervical cancer (unlabeled use):",
"     </b>",
"     I.V.: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 3 weeks (in combination with fluorouracil and radiation) for 3 cycles (Morris, 1999)",
"     <b>",
"      or",
"     </b>",
"     70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 3 weeks for 4 cycles (in combination with fluorouracil; cycles 1 and 2 given concurrently with radiation) (Peters, 2000)",
"     <b>",
"      or",
"     </b>",
"     50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 4 weeks (in combination with radiation and fluorouracil) for 2 cycles (Whitney, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endometrial carcinoma, recurrent, metastatic, or high-risk (unlabeled use):",
"     </b>",
"     I.V.: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 3 weeks (in combination with doxorubicin &plusmn; paclitaxel) for 7 cycles or until disease progression or unacceptable toxicity (Fleming, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Head and neck cancer (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Locally-advanced disease:",
"     </i>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks for 3 doses (with concurrent radiation) (Bernier, 2004; Cooper, 2004)",
"     <b>",
"      or",
"     </b>",
"     75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (in combination with docetaxel and fluorouracil) for 4 cycles or until disease progression or unacceptable toxicity (if no disease progression after 4 cycles, chemotherapy was followed by radiation) (Vermorken, 2007)",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (in combination with docetaxel and fluorouracil) for 3 cycles or until disease progression or unacceptable toxicity (chemotherapy was followed by chemoradiation) (Posner, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Metastatic disease:",
"     </i>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (in combination with fluorouracil and cetuximab) until disease progression or unacceptable toxicity or a maximum of 6 cycles (Vermorken, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malignant pleural mesothelioma (unlabeled use):",
"     </b>",
"     I.V.: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of each 21-day cycle (in combination with pemetrexed) (Vogelzang, 2003)",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of a 28-day cycle (in combination with gemcitabine) (Nowak, 2002)",
"     <b>",
"      or",
"     </b>",
"     80 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of a 21-day cycle (in combination with gemcitabine) (van Haarst, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      NSCLC (unlabeled use):",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     There are multiple cisplatin-containing regimens for the treatment of NSCLC. Listed below are several commonly used regimens:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 4 weeks (in combination with etoposide) for 3-4 cycles; (Arriagada, 2007), or",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 4 weeks (in combination with vinorelbine) (Kelly, 2001; Wozniak, 1998), or",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 4 weeks (in combination with gemcitabine) (Comella, 2000), or",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 3 weeks (in combination with gemcitabine) (Ohe, 2007), or",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 3 weeks (in combination with pemetrexed) for up to 6 cycles or until disease progression or unacceptable toxicity (Scagliotti, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer (unlabeled route):",
"     </b>",
"     Intraperitoneal: 75-100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 2 of a 21-day treatment cycle (in combination with I.V. and intraperitoneal paclitaxel) for 6 cycles (Armstrong, 2006; NCCN Ovarian Cancer guidelines, v.1.2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      SCLC (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Limited-stage disease:",
"     </i>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 3 weeks for 4 cycles (in combination with etoposide and concurrent radiation) (Turrisi, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extensive-stage disease:",
"     </i>",
"     80 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 3 weeks (in combination with etoposide) for 4 cycles (Lara, 2009) or a maximum of 8 cycles (Ihde, 1994)",
"     <b>",
"      or",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 4 weeks for 4 cycles (in combination with irinotecan) (Lara, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Testicular germ cell tumor, malignant (unlabeled use):",
"     </b>",
"     I.V.: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 2-5 every 3 weeks (in combination with paclitaxel and ifosfamide) for 4 cycles (Kondagunta, 2005)",
"     <b>",
"      or",
"     </b>",
"     20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1-5 every 3 weeks (in combination with bleomycin and etoposide) for 4 cycles (Nichols, 1998)",
"     <b>",
"      or",
"     </b>",
"     20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1-5 every 3 weeks (in combination with etoposide and ifosfamide) for 4 cycles (Nichols, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F151906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/8/34949?source=see_link\">",
"      see \"Cisplatin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      VERIFY ANY CISPLATIN DOSE EXCEEDING 100 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      PER COURSE.",
"     </b>",
"     Pretreatment hydration is recommended. Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Germ cell tumors (unlabeled use; combination chemotherapy):",
"     </b>",
"     I.V.: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1-5 or 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of a 21-day treatment cycle (Pinkerton, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hepatoblastoma (unlabeled use; combination chemotherapy):",
"     </b>",
"     I.V.: 80 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     continuous infusion over 24 hours on day 1 of a 21-day treatment cycle (Pritchard, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Medulloblastoma (unlabeled use; combination chemotherapy):",
"     </b>",
"     I.V.: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on either day 0 or day 1 of each chemotherapy cycle (Packer, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neuroblastoma, high-risk (unlabeled use; combination chemotherapy):",
"     </b>",
"     I.V.: 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 0-3 of a 21-day cycle (cycles 3 and 5) (Naranjo, 2011)",
"     <b>",
"      or",
"     </b>",
"     50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1-4 (cycles 3, 5, and 7) (Kushner, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteosarcoma (unlabeled use; combination chemotherapy):",
"     </b>",
"     I.V.: 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2 days weeks 2, 7, 25, and 28 (neoadjuvant)  or weeks 5, 10, 25, and 28 (adjuvant) (Goorin, 2003)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F151884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Select dose cautiously and monitor closely in the elderly; may be more susceptible to nephrotoxicity and peripheral neuropathy.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F151885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer(s) recommend that repeat courses of cisplatin should not be given until serum creatinine is &lt;1.5 mg/dL and/or BUN is &lt;25 mg/dL and use is contraindicated in pre-existing renal impairment. The following adjustments have been recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aronoff, 2007:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Partially cleared by hemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Administer 50% of dose posthemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Janus, 2010: Hemodialysis: Reduce initial dose by 50%; administer post hemodialysis or on nondialysis days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Kintzel, 1995:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Consider use of alternative drug",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15577361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, cisplatin undergoes nonenzymatic metabolism and predominantly renal elimination;  therefore, dosage adjustment is likely not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F151858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 1 mg/mL (50 mL, 100 mL, 200 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F151843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F151861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pretreatment hydration with 1-2 L of fluid is recommended prior to cisplatin administration; adequate post hydration and urinary output (&gt;100 mL/hour) should be maintained for 24 hours after administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Infuse over 6- 8 hours; has also been infused (unlabeled rates) over 30 minutes to 3 hours, at a rate of 1 mg/minute, or as a continuous infusion; infusion rate varies by protocol (refer to specific protocol for infusion details). Avoid extravasation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Needles or I.V. administration sets that contain aluminum should not be used in the preparation or administration; aluminum can react with cisplatin resulting in precipitate formation and loss of potency.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F151935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with sodium bicarbonate;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, anidulafungin, aztreonam, bleomycin, caspofungin, chlorpromazine, cimetidine, cladribine, cyclophosphamide, dexamethasone sodium phosphate, diphenhydramine, doripenem, doxorubicin, doxorubicin liposome, droperidol, etoposide phosphate, famotidine, filgrastim, fludarabine, fluorouracil, furosemide, ganciclovir, gemcitabine, granisetron, heparin, hydromorphone, leucovorin calcium, linezolid, lorazepam, melphalan, methotrexate, methylprednisolone sodium succinate, mitomycin, ondansetron, paclitaxel, palonosetron, pemetrexed, prochlorperazine edisylate, promethazine, propofol, ranitidine, sargramostim, teniposide, topotecan, vinblastine, vincristine, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amifostine, amphotericin B cholesteryl sulfate complex, cefepime, gallium nitrate, piperacillin/tazobactam, thiotepa.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Metoclopramide.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F151859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of advanced bladder cancer, metastatic testicular cancer, and metastatic ovarian cancer",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F2523501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of breast cancer (metastatic), central nervous system tumors, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, germ cell tumors, gestational trophoblastic disease (refractory), head and neck cancer, hepatobiliary cancer, hepatoblastoma, Hodgkin lymphoma, malignant pleural mesothelioma, melanoma (metastatic), multiple myeloma, neuroblastoma, neuroendocrine tumors, non-Hodgkin lymphoma (NHL), nonsmall cell lung cancer (NSCLC), osteosarcoma, pancreatic cancer (advanced), prostate cancer, small cell lung cancer (SCLC), soft tissue sarcomas, and unknown primary cancers",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F151938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       CISplatin may be confused with CARBOplatin, oxaliplatin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Doses  &gt;100 mg/m",
"       <sup>",
"        2",
"       </sup>",
"       once every 3-4 weeks are rarely used and should be verified with the prescriber.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F151926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Neurotoxicity: Peripheral neuropathy is dose- and duration-dependent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea and vomiting (76% to 100%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (&le;40%), leukopenia (25% to 30%; nadir: Day 18-23; recovery: By day 39; dose related), thrombocytopenia (25% to 30%; nadir: Day 18-23; recovery: By day 39; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Nephrotoxicity (28% to 36%; acute renal failure and chronic renal insufficiency)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ototoxicity (children 40% to 60%; adults 10% to 31%; as tinnitus, high frequency hearing loss)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Local: Tissue irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia (mild), anaphylactic reaction, arrhythmias, arterial vasospasm (acute), autonomic neuropathy, bradycardia, bronchoconstriction, cerebral arteritis, cerebrovascular accident, dehydration, extravasation injury, heart block, heart failure, hemolytic anemia (acute), hemolytic uremic syndrome, hypercholesterolemia, hyperuricemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, hypotension, leukoencephalopathy, Lhermitte's phenomenon, limb ischemia (acute), mesenteric ischemia (acute), mouth sores, myocardial infarction, myocardial ischemia, neutropenic typhlitis, optic neuritis, orthostatic hypotension, pancreatitis, papilledema, phlebitis, reversible posterior leukoencephalopathy syndrome (RPLS), seizures, serum amylase increased, SIADH, spinal cord injury, stroke, tachycardia, tetany, thrombophlebitis, thrombotic microangiopathy, thrombotic thrombocytopenic purpura, vision loss, visual color perception changes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F151864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cisplatin, other platinum-containing compounds, or any component of the formulation (anaphylactic-like reactions have been reported); pre-existing renal impairment; myelosuppression; hearing impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F151847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Myelosuppression is a dose-related toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal toxicity: Nausea and vomiting are dose-related toxicities; antiemetics are recommended. Nausea and vomiting may be immediate and/or delayed. Diarrhea may also occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactoid reactions:",
"     <b>",
"      [U.S. Boxed Warnings]: Anaphylactic-like reactions have been reported; may include facial edema, bronchoconstriction, tachycardia, and hypotension and may occur within minutes of administration. May be managed with epinephrine, corticosteroids, and/or antihistamines.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperuricemia: Hyperuricemia has been reported with cisplatin use, and is more pronounced with doses &gt;50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; consider allopurinol therapy to reduce uric acid levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion site reactions: Local infusion site reactions may occur; monitor infusion site during administration; avoid extravasation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity: Severe (and possibly irreversible) neuropathies may occur with higher than recommended doses or more frequent  administration; may require therapy discontinuation. Seizures, loss of motor function, loss of taste, leukoencephalopathy, and posterior reversible leukoencephalopathy syndrome (PRES [formerly RPLS]) have also been described.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ototoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Ototoxicity, especially pronounced in children, is manifested by tinnitus or loss of high frequency hearing and occasionally, deafness; may be significant.",
"     </b>",
"     Pediatric patients with certain genetic variations in the thiopurine S-methyltransferase (TPMT) gene may be at increased risk of ototoxicity, even when conventional cisplatin doses are given. Ototoxicity is cumulative; audiometric testing should be performed at baseline, and prior to each dose. Pediatric patients should receive audiometric testing for several years after discontinuing therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Cumulative renal toxicity may be severe.",
"     </b>",
"     Monitor serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes closely. According to the manufacturer&rsquo;s labeling, use is contraindicated in patients with preexisting renal impairment and renal function must return to normal prior to administering subsequent cycles; some literature recommends reduced doses with renal impairment. Nephrotoxicity may be potentiated by aminoglycosides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancies: Secondary malignancies have been reported with cisplatin in combination with other chemotherapy agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in the elderly; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria). Select dose cautiously and monitor closely in the elderly; may be more susceptible to nephrotoxicity and peripheral neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Medication safety (usual maximum dose per cycle):",
"     <b>",
"      [U.S. Boxed Warning]: Doses &gt;100 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      once every 3-4 weeks are rarely used; verify with the prescriber. Exercise caution to avoid potential sound-alike/look-alike confusion between CISplatin and CARBOplatin.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hydration: Patients should receive adequate hydration, with or without diuretics, prior to and for 24 hours after administration; serum electrolytes, particularly magnesium and potassium, should be monitored and replaced as needed during and after therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F151852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: CISplatin may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: CISplatin may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: CISplatin may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Taxane Derivatives: Platinum Derivatives may enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: Platinum Derivatives may enhance the adverse/toxic effect of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vinorelbine: CISplatin may enhance the adverse/toxic effect of Vinorelbine. Specifically, the combination may be associated with a higher risk of granulocytopenia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F151854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2523502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenicity and embryotoxicity. Women of childbearing potential should be advised to avoid pregnancy. If used in pregnancy, or if patient becomes pregnant during treatment, the patient should be apprised of potential hazard to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F151893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15577338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cisplatin is excreted in breast milk. Per the manufacturer, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F151867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (CISplatin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/50 mL (50 mL): $21.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/100 mL (100 mL): $43.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/200 mL (200 mL): $86.64",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F151856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function (serum creatinine, BUN, Cl",
"     <sub>",
"      cr",
"     </sub>",
"     ); electrolytes (particularly magnesium, calcium, potassium [periodic]); CBC with differential and platelet count (weekly); liver function tests (periodic); audiography (baseline and prior to each subsequent dose, and following treatment in children), neurologic exam (with high dose); urine output, urinalysis",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F151868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abiplatin (IL, NZ, TW);",
"     </li>",
"     <li>",
"      Bioplatino (PE);",
"     </li>",
"     <li>",
"      Blastolem (CN, CO);",
"     </li>",
"     <li>",
"      Blastolem RU (MX);",
"     </li>",
"     <li>",
"      Cisly (LU);",
"     </li>",
"     <li>",
"      Cispatin (KP);",
"     </li>",
"     <li>",
"      Cisplatin (AU, ID, IN, NZ);",
"     </li>",
"     <li>",
"      Cisplatin Ebewe (HU);",
"     </li>",
"     <li>",
"      Cisplatin medac (LU);",
"     </li>",
"     <li>",
"      Cisplatin Teva (HU);",
"     </li>",
"     <li>",
"      Cisplatin-Ebewe (MY);",
"     </li>",
"     <li>",
"      Cisplatine-Lilly (LU);",
"     </li>",
"     <li>",
"      Cisplatino (CO, ES, PE);",
"     </li>",
"     <li>",
"      Cisplatinum Cytosafe-Delta West (LU);",
"     </li>",
"     <li>",
"      Cisplatyl (BR, FR);",
"     </li>",
"     <li>",
"      Cisteen (PH);",
"     </li>",
"     <li>",
"      Citoplatino (IT);",
"     </li>",
"     <li>",
"      Cysplack (PH);",
"     </li>",
"     <li>",
"      Elvecis (AR);",
"     </li>",
"     <li>",
"      Fang tan (CL);",
"     </li>",
"     <li>",
"      Kemoplat (IN, PH, SG, TW);",
"     </li>",
"     <li>",
"      Lederplatin (DK);",
"     </li>",
"     <li>",
"      Neoplatin (ES);",
"     </li>",
"     <li>",
"      Oncotin (PH);",
"     </li>",
"     <li>",
"      P&amp;U Cisplatin (ZA);",
"     </li>",
"     <li>",
"      Placis (ES, TR);",
"     </li>",
"     <li>",
"      Platamine (AE, BH, CY, EG, HR, IQ, IR, IT, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Platiblastin (CH, DE);",
"     </li>",
"     <li>",
"      Platidiam (BG, CZ, HN, HU, PL, RU);",
"     </li>",
"     <li>",
"      Platimit (HR);",
"     </li>",
"     <li>",
"      Platin (PH);",
"     </li>",
"     <li>",
"      Platinex (HR, IT, TW);",
"     </li>",
"     <li>",
"      Platinil (BR);",
"     </li>",
"     <li>",
"      Platinol (AR, AT, BE, CH, EE, FI, GR, LU, NO, SE, UY);",
"     </li>",
"     <li>",
"      Platistil (ES, PT);",
"     </li>",
"     <li>",
"      Platistin (FI, NO, SE);",
"     </li>",
"     <li>",
"      Platistine (LU);",
"     </li>",
"     <li>",
"      Platosin (GB, KP, MY, NL, PK, TH);",
"     </li>",
"     <li>",
"      Randa (JP);",
"     </li>",
"     <li>",
"      Sicatem (PY);",
"     </li>",
"     <li>",
"      Sinplatin (BG);",
"     </li>",
"     <li>",
"      Tecnoplatin (MX);",
"     </li>",
"     <li>",
"      Unistin (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F151846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA synthesis by the formation of DNA cross-links; denatures the double helix; covalently binds to DNA bases and disrupts DNA function; may also bind to proteins; the",
"     <i>",
"      cis",
"     </i>",
"     -isomer is 14 times more cytotoxic than the",
"     <i>",
"      trans",
"     </i>",
"     -isomer; both forms cross-link DNA but cis-platinum is less easily recognized by cell enzymes and, therefore, not repaired. Cisplatin can also bind two adjacent guanines on the same strand of DNA producing intrastrand cross-linking and breakage.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F151863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: I.V.: Rapidly into tissue; high concentrations in kidneys, liver, ovaries, uterus, and lungs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;90% (O'Dwyer, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Nonenzymatic; inactivated (in both cell and bloodstream) by sulfhydryl groups; covalently binds to glutathione and thiosulfate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Initial: 14-49 minutes; Beta: 0.7-4.6 hours; Gamma: 24-127 hours (O'Dwyer, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&gt;90%); feces (minimal)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Armstrong DK, Bundy B, Wenzel L, et al, &ldquo;Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(1):34-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/16394300/pubmed\" id=\"16394300\" target=\"_blank\">",
"        16394300",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 170.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arriagada R, Bergman B, Dunant A, et al, \"Cisplatin-Based Adjuvant Chemotherapy in Patients With Completely Resected Non-Small-Cell Lung Cancer,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(4):351-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/14736927/pubmed\" id=\"14736927\" target=\"_blank\">",
"        14736927",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bernier J, Domenge C, Ozsahin M, et al, &ldquo;Postoperative Irradiation With or Without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(19):1945-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/15128894/pubmed\" id=\"15128894\" target=\"_blank\">",
"        15128894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cascinu S, Fedeli A, Del Ferro E, et al, \"Recombinant Human Erythropoietin Treatment in Cisplatin-Associated Anemia: A Randomized, Double-Blind Trial With Placebo,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1994, 12(5):1058-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/8164030/pubmed\" id=\"8164030\" target=\"_blank\">",
"        8164030",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Colucci G, Labianca R, Di Costanzo F, et al, &ldquo;Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(10):1645-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/20194854/pubmed\" id=\"20194854\" target=\"_blank\">",
"        20194854",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Comella P, Frasci G, Panza N, et al, \"Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non-Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(7):1451-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/10735892/pubmed\" id=\"10735892\" target=\"_blank\">",
"        10735892",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper JS, Pajak TF, Forastiere AA, et al, &ldquo;Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(19):1937-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/15128893/pubmed\" id=\"15128893\" target=\"_blank\">",
"        15128893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Costello MA, Dominick C, and Clerico A, &ldquo;A Pilot Study of 5-Day Continuous Infusion of High-Dose Cisplatin and Pulsed Etoposide in Childhood Solid Tumors,&rdquo;",
"      <i>",
"       Am J Pediatr Hematol Oncol",
"      </i>",
"      , 1988, 10:103-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cushing B, Giller R, Cullen JW, et al, &ldquo;Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study -- Pediatric Oncology Group 9049 and Children's Cancer Group 8882,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(13):2691-700.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/15226336/pubmed\" id=\"15226336\" target=\"_blank\">",
"        15226336",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dupuis LL, Boodhan S, Sung L, &ldquo;Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2011, 57(2):191-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/21465637/pubmed\" id=\"21465637\" target=\"_blank\">",
"        21465637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eton O, Legha SS, Bedikian AY, et al, &ldquo;Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(8):2045-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/11956264/pubmed\" id=\"11956264\" target=\"_blank\">",
"        11956264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farris FF, Dedrick RL, and King FG, \"Cisplatin Pharmacokinetics: Applications of a Physiological Model,\"",
"      <i>",
"       Toxicol Lett",
"      </i>",
"      , 1988, 43(1-3):117-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/3051521/pubmed\" id=\"3051521\" target=\"_blank\">",
"        3051521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fernandex de Larrea C, Martinez C, Gaya A, et al, &ldquo;Salvage Chemotherapy With Alternating MINE-ESHAP Regimen in Relapsed or Refractory Hodgkin&rsquo;s Lymphoma Followed By Autologous Stem-Cell Transplantation,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(6):1211-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/19889622/pubmed\" id=\"19889622\" target=\"_blank\">",
"        19889622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleming GF, Brunetto VL, Cella D, et al, &ldquo;Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(11):2159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/15169803/pubmed\" id=\"15169803\" target=\"_blank\">",
"        15169803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Go RS and Adjei AA, \"Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(1):409-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/10458260/pubmed\" id=\"10458260\" target=\"_blank\">",
"        10458260",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goorin AM, Schwartzentruber DJ, Devidas M, et al, &ldquo;Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(8):1574-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/12697883/pubmed\" id=\"12697883\" target=\"_blank\">",
"        12697883",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greco FA, Erland JB, Morrissey LH, et al, \"Carcinoma of Unknown Primary Site: Phase II Trials With Docetaxel Plus Cisplatin or Carboplatin,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2000, 11(2):211-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/10761758/pubmed\" id=\"10761758\" target=\"_blank\">",
"        10761758",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hebert ME, Blivin JL, Kessler J, et al, &ldquo;Anaphylactoid Reactions With Intraperitoneal Cisplatin,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(3):260-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/7606071/pubmed\" id=\"7606071\" target=\"_blank\">",
"        7606071",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Higa GM, Wise TC, and Crowell EB, &ldquo;Severe, Disabling Neurologic Toxicity Following Cisplatin Retreatment,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(2):134-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/7756711/pubmed\" id=\"7756711\" target=\"_blank\">",
"        7756711",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howell SB, Pfeifle CL, Wung WE, et al, &ldquo;Intraperitoneal Cisplatin With Systemic Thiosulfate Protection,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1982, 97(6):845-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/6890785/pubmed\" id=\"6890785\" target=\"_blank\">",
"        6890785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ihde DC, Mulshine JL, Kramer BS, et al, &ldquo;Prospective Randomized Comparison of High-Dose and Standard-Dose Etoposide and Cisplatin Chemotherapy in Patients With Extensive-Stage Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1994, 12(10):2022-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/7931470/pubmed\" id=\"7931470\" target=\"_blank\">",
"        7931470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Janus N, Thariat J, Boulanger H, et al, &ldquo;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(7):1395-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/20118214/pubmed\" id=\"20118214\" target=\"_blank\">",
"        20118214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly K, Crowley J, Bunn PA Jr, et al, &ldquo;Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Nonsmall-Cell Lung Cancer: A Southwest Oncology Group Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(13):3210-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/11432888/pubmed\" id=\"11432888\" target=\"_blank\">",
"        11432888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kondagunta GV, Bacik J, Donadio A, et al, &ldquo;Combination of Paclitaxel, Ifosfamide, and Cisplatin is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(27):6549-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/16170162/pubmed\" id=\"16170162\" target=\"_blank\">",
"        16170162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kushner BH, LaQuaglia MP, Bonilla MA, et al, &ldquo;Highly Effective Induction Therapy for Stage 4 Neuroblastoma in Children Over 1 Year of Age,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1994, 12(12):2607-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/7527454 /pubmed\" id=\"7527454 \" target=\"_blank\">",
"        7527454",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lara PN Jr, Natale R, Crowley J, et al, &ldquo;Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(15):2530-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/19349543/pubmed\" id=\"19349543\" target=\"_blank\">",
"        19349543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morris M, Eifel PJ, Lu J, et al, &ldquo;Pelvic Radiation With Concurrent Chemotherapy Compared With Pelvic and Para-aortic Radiation for High-Risk Cervical Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(15):1137-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/10202164 /pubmed\" id=\"10202164 \" target=\"_blank\">",
"        10202164",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Naranjo A, Parisi MT, Shulkin BL, et al, &ldquo;Comparison of",
"      <sup>",
"       123",
"      </sup>",
"      I-metaiodobenzylguanidine (MIBG) and",
"      <sup>",
"       131",
"      </sup>",
"      I-MIBG Semi-Quantitative Scores in Predicting Survival in Patients With Stage 4 Neuroblastoma: A Report from the Children&rsquo;s Oncology Group,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2011, 56(7):1041-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/21328522/pubmed\" id=\"21328522\" target=\"_blank\">",
"        21328522",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Ovarian Cancer,&rdquo; Version 1.2013. Available at file://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newlands ES, Bower M, Holden L, et al, &ldquo;Management of Resistant Gestational Trophoblastic Tumors,&rdquo;",
"      <i>",
"       J Reprod Med",
"      </i>",
"      , 1998, 43(2):111-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/9513872 /pubmed\" id=\"9513872 \" target=\"_blank\">",
"        9513872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newlands ES, Mulholland PJ, Holden L, et al, &ldquo;Etoposide and Cisplatin/Etoposide, Methotrexate, and Actinomycin D (EMA) Chemotherapy for Patients With High-Risk Gestational Trophoblastic Tumors Refractory to EMA/Cyclophosphamide and Vincristine Chemotherapy and Patients Presenting With Metastatic Placental Site Trophoblastic Tumors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(4):854-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/10673528/pubmed\" id=\"10673528\" target=\"_blank\">",
"        10673528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nichols CR, Catalano PJ, Crawford ED, et al, &ldquo;Randomized Comparison of Cisplatin and Etoposide and Either Bleomycin or Ifosfamide in Treatment of Advanced Disseminated Germ Cell Tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(4):1287-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/9552027 /pubmed\" id=\"9552027 \" target=\"_blank\">",
"        9552027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nowak AK, Byrne MJ, Williamson R, et al, &ldquo;A Multicentre Phase II Study of Cisplatin and Gemcitabine for Malignant Mesothelioma,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2002, 87(5):491-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/12189542/pubmed\" id=\"12189542\" target=\"_blank\">",
"        12189542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Dwyer PJ, Stevenson JP and Johnson SW, &ldquo;Clinical Pharmacokinetics and Administration of Established platinum drugs,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2000, 59 (Suppl 4):19-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/10864227/pubmed\" id=\"10864227\" target=\"_blank\">",
"        10864227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohe Y, Ohashi Y, Kubota K, et al, \"Randomized Phase III Study of Cisplatin Plus Irinotecan Versus Carboplatin Plus Paclitaxel, Cisplatin Plus Gemcitabine, and Cisplatin Plus Vinorelbine for Advanced Non-Small-Cell Lung Cancer: Four-Arm Cooperative Study in Japan,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2007, 18(2):317-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/17079694/pubmed\" id=\"17079694\" target=\"_blank\">",
"        17079694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ozols RF, Bundy BN, Greer BE, et al, \"Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(17):3194-200.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/12860964 /pubmed\" id=\"12860964 \" target=\"_blank\">",
"        12860964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer RJ, Gajjar A, Vezina G, et al, &ldquo;Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(25):4202-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/16943538/pubmed\" id=\"16943538\" target=\"_blank\">",
"        16943538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pegram MD, Pienkowski T, Northfelt DW, et al, \"Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer,\"",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2004, 96(10):759-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/15150304/pubmed\" id=\"15150304\" target=\"_blank\">",
"        15150304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al, \"Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(8):1606-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/10764420/pubmed\" id=\"10764420\" target=\"_blank\">",
"        10764420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pinkerton CR, Pritchard J, and Spitz L, &ldquo;High Complete Response Rate in Children With Advanced Germ Cell Tumors Using Cisplatin-Containing Combination Chemotherapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1986, 4(2):194-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/2418168/pubmed\" id=\"2418168\" target=\"_blank\">",
"        2418168",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Posner MR, Hershock DM, Blajman CR, et al, \"Cisplatin and Fluorouracil Alone or With Docetaxel in Head and Neck Cancer,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(17):1705-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/17960013/pubmed\" id=\"17960013\" target=\"_blank\">",
"        17960013",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pritchard J, Brown J, Shafford E, et al, &ldquo;Cisplatin, Doxorubicin, and Delayed Surgery for Childhood Hepatoblastoma: A Successful Approach--Results of the First Prospective Study of the International Society of Pediatric Oncology,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(22):3819-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/11078495/pubmed\" id=\"11078495\" target=\"_blank\">",
"        11078495",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reece PA, Stafford I, Abbott RL, et al, &ldquo;Two- Versus 24-Hour Infusion of Cisplatin: Pharmacokinetic Considerations,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1989, 7(2):270-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/2536803/pubmed\" id=\"2536803\" target=\"_blank\">",
"        2536803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez MA, Cabanillas FC, Velasquez W, et al, &ldquo;Results of a Salvage Treatment Program for Relapsing Lymphoma: MINE Consolidated With ESHAP,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1995, 13(7):1734-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/7602363 /pubmed\" id=\"7602363 \" target=\"_blank\">",
"        7602363",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rothmann SA and Weick JK, &ldquo;Cisplatin Toxicity for Erythroid Precursors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1981, 304(6):360.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/7192364/pubmed\" id=\"7192364\" target=\"_blank\">",
"        7192364",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saxman SB, Finch D, Gonin R, et al, &ldquo;Long-Term Follow-Up of a Phase III Study of Three Versus Four Cycles of Bleomycin, Etoposide, and Cisplatin in Favorable-Prognosis Germ-Cell Tumors: The Indian University Experience,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(2):702-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/9469360/pubmed\" id=\"9469360\" target=\"_blank\">",
"        9469360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scagliotti GV, Parikh P, von Pawel J, et al, \"Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(21):3543-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/18506025/pubmed\" id=\"18506025\" target=\"_blank\">",
"        18506025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schilsky RL and Anderson T, &ldquo;Hypomagnesemia and Renal Magnesium Wasting in Patients Receiving Cisplatin,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1979, 90(6):929-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/375794/pubmed\" id=\"375794\" target=\"_blank\">",
"        375794",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuchter LM, Hensley ML, Meropol NJ, et al, &ldquo;2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(12):2895-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/12065567/pubmed\" id=\"12065567\" target=\"_blank\">",
"        12065567",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shlebak AA, Clark PI, and Green JA, &ldquo;Hypersensitivity and Cross-Reactivity to Cisplatin and Analogues,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1995, 35(4):349-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/7828281/pubmed\" id=\"7828281\" target=\"_blank\">",
"        7828281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Turrisi AT, Kim K, Blum R, et al, &ldquo;Twice-Daily Compared With Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently With Cisplatin and Etoposide,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(4):265-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/9920950/pubmed\" id=\"9920950\" target=\"_blank\">",
"        9920950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Haarst JM, Baas P, Manegold Ch, et al, &ldquo;Multicentre Phase II Study of Gemcitabine and Cisplatin in Malignant Pleural Mesothelioma,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2002, 86(3):342-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/11875695 /pubmed\" id=\"11875695 \" target=\"_blank\">",
"        11875695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vermorken JB, Mesia R, Rivera F, et al, \"Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(11):1116-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/18784101/pubmed\" id=\"18784101\" target=\"_blank\">",
"        18784101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vermorken JB, Remenar E, van Herpen C, et al, \"Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(17):1695-1704.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/17960012/pubmed\" id=\"17960012\" target=\"_blank\">",
"        17960012",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vogelzang NJ, Rusthoven JJ, Symanowski J, et al, &ldquo;Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(14):2636-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/12860938/pubmed\" id=\"12860938\" target=\"_blank\">",
"        12860938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Whitney CW, Sause W, Bundy BN, et al, &ldquo;Randomized Comparison of Fluorouracil Plus Cisplatin Versus Hydroxyurea as an Adjunct to Radiation Therapy in Stage IIB-IVA Carcinoma of the Cervix With Negative Para-aortic Lymph Nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(5):1339-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/10334517 /pubmed\" id=\"10334517 \" target=\"_blank\">",
"        10334517",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wozniak AJ, Crowley JJ, Balcerzak SP, et al, &ldquo;Randomized Trial Comparing Cisplatin With Cisplatin Plus Vinorelbine in the Treatment of Advanced Nonsmall-Cell Lung Cancer: A Southwest Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(7):2459-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/51/21305/abstract-text/9667264/pubmed\" id=\"9667264\" target=\"_blank\">",
"        9667264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9271 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-218.189.88.190-EF2F3CD7BB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_51_21305=[""].join("\n");
var outline_f20_51_21305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708671\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151928\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151883\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151906\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151884\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151885\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15577361\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151858\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151843\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151861\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151935\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151859\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523501\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151938\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151926\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151864\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151847\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299049\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151852\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151854\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523502\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151893\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15577338\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151867\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323068\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151856\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151868\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151846\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151863\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9271\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9271|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/20/14661?source=related_link\">",
"      Cisplatin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/8/34949?source=related_link\">",
"      Cisplatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_51_21306="Evaluation and management of severe sepsis and septic shock in adults";
var content_f20_51_21306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of severe sepsis and septic shock in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/51/21306/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/51/21306/contributors\">",
"     Gregory A Schmidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/51/21306/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/51/21306/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/51/21306/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/51/21306/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/51/21306/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/51/21306/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/51/21306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis is a clinical syndrome characterized by systemic inflammation due to infection. There is a continuum of severity ranging from sepsis to severe sepsis and septic shock. Over 1,665,000 cases of sepsis occur in the United States each year, with a mortality rate of 20 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/1\">",
"     1",
"    </a>",
"    ]. Even with optimal treatment, mortality due to severe sepsis or septic shock is approximately 40 percent and can exceed 50 percent in the sickest patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous interventions exist that decrease mortality due to sepsis. In this topic review, the management of severe sepsis and septic shock is discussed. Definitions, diagnosis, pathophysiology, and investigational therapies are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=see_link\">",
"     \"Pathophysiology of sepsis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29960?source=see_link\">",
"     \"Investigational and ineffective therapies for sepsis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THERAPEUTIC PRIORITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic priorities for patients with severe sepsis or septic shock include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early initiation of supportive care to correct physiologic abnormalities, such as hypoxemia and hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/6-10\">",
"       6-10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Distinguishing sepsis from systemic inflammatory response syndrome (SIRS) (",
"      <a class=\"graphic graphic_table graphicRef68887 \" href=\"UTD.htm?7/32/7691\">",
"       table 1",
"      </a>",
"      ) because, if an infection exists, it must be identified and treated as soon as possible (",
"      <a class=\"graphic graphic_table graphicRef58257 \" href=\"UTD.htm?6/4/6220\">",
"       table 2",
"      </a>",
"      ). This may require a surgical procedure (eg, drainage), as well as appropriate antibiotics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EARLY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first priority in any patient with severe sepsis or septic shock is stabilization of their airway and breathing. Next, perfusion to the peripheral tissues should be restored [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Stabilize respiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen should be supplied to all patients with sepsis and oxygenation should be monitored continuously with pulse oximetry. Intubation and mechanical ventilation may be required to support the increased work of breathing that typically accompanies sepsis, or for airway protection since encephalopathy and a depressed level of consciousness frequently complicate sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sedative and induction agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    ) used to intubate patients with severe sepsis or septic shock are discussed separately. Other aspects of intubation and mechanical ventilation are similarly described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=see_link\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=see_link\">",
"     \"Advanced emergency airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=see_link\">",
"     \"The decision to intubate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chest radiographs and arterial blood analysis should be obtained following initial stabilization. These studies are used in combination with other clinical parameters to diagnose acute respiratory distress syndrome (ARDS), which frequently complicate sepsis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Assess perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the patient's respiratory status has been stabilized, the adequacy of perfusion should be assessed. Hypotension is the most common indicator that perfusion is inadequate (eg, systolic blood pressure (SBP) &lt;90 mmHg, mean arterial pressure &lt;70 mmHg, decrease in SBP &gt;40 mmHg). Therefore, it is important that the blood pressure be assessed early and often. An arterial catheter may be inserted if blood pressure is labile or restoration of arterial perfusion pressures is expected to be a protracted process, because a sphygmomanometer may be unreliable in hypotensive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/8\">",
"     8",
"    </a>",
"    ]. Attempts to insert an arterial line should not be allowed to delay the prompt management of shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26424?source=see_link\">",
"     \"Arterial catheterization techniques for invasive monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Critical hypoperfusion can also occur in the absence of hypotension, especially during early sepsis. Thus, clinical evidence of impaired perfusion should be sought in all patients with sepsis. Common signs of hypoperfusion include cool, vasoconstricted skin due to redirection of blood flow to core organs (although warm, flushed skin may be present in the early phases of sepsis), tachycardia",
"    <span class=\"nowrap\">",
"     &gt;90/min,",
"    </span>",
"    obtundation or restlessness, and oliguria or anuria. These findings may be modified by preexisting disease or medications. As an example, elderly patients, diabetic patients, and patients who take beta-blockers may not exhibit an appropriate tachycardia as blood pressure falls. Patients with chronic hypertension may develop critical hypoperfusion at a higher blood pressure than healthy patients (ie, relative hypotension).",
"   </p>",
"   <p>",
"    An elevated serum lactate (eg, &gt;1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    can be a manifestation of organ hypoperfusion in the absence of hypotension and is an important component of the initial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/10\">",
"     10",
"    </a>",
"    ]. A serum lactate level &ge;4",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    is consistent with severe sepsis. Additional laboratory studies that help characterize the severity of sepsis include the platelet count, international normalized ratio, creatinine, and bilirubin. Values for laboratory parameters that suggest severe sepsis are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link&amp;anchor=H7#H7\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\", section on 'Severe sepsis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Establish central venous access",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial assessment, a central venous catheter (CVC) should be inserted in most patients with severe sepsis or septic shock. A CVC can be used to infuse intravenous fluids, infuse medications, infuse blood products, and draw blood. In addition, it can be used for hemodynamic monitoring by measuring the central venous pressure (CVP) and the central venous oxyhemoglobin saturation (ScvO",
"    <sub>",
"     2",
"    </sub>",
"    ). In one clinical trial, treatment of septic shock guided by the ScvO",
"    <sub>",
"     2",
"    </sub>",
"    reduced mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We believe that pulmonary artery catheters (PACs) should",
"    <strong>",
"     not",
"    </strong>",
"    be used in the routine management of patients with severe sepsis or septic shock. PACs can measure the pulmonary artery occlusion pressure (PAOP) and mixed venous oxyhemoglobin saturation (SvO",
"    <sub>",
"     2",
"    </sub>",
"    ). In theory, this may be helpful to guide circulatory resuscitation. However, the PAOP has proven to be a poor predictor of fluid responsiveness in sepsis and the SvO",
"    <sub>",
"     2",
"    </sub>",
"    is similar to the ScvO",
"    <sub>",
"     2",
"    </sub>",
"    , which can be obtained from a CVC [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. PACs increase complications and have not been shown to improve outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Respiratory changes in the radial artery pulse pressure, aortic blood flow peak velocity, and brachial artery blood flow velocity are considered dynamic hemodynamic measures, whereas CVP and PAOP are considered static hemodynamic measures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. There is increasing evidence that dynamic measures are more accurate predictors of fluid responsiveness than static measures, as long as the patients are in sinus rhythm and passively ventilated with a sufficient tidal volume [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/15,22,23\">",
"     15,22,23",
"    </a>",
"    ]. For actively breathing patients or those with irregular cardiac rhythms, an increase in the cardiac output in response to a passive leg-raising maneuver (measured by echocardiography, arterial pulse waveform analysis, or pulmonary artery catheterization) is a sensitive and specific predictor of fluid responsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/24\">",
"     24",
"    </a>",
"    ]. It seems likely that dynamic measures will become more common and be used to identify patients who are likely to increase organ perfusion in response to intravenous fluids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3877337\">",
"    <span class=\"h2\">",
"     Goals of initial resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once it has been established that hypoperfusion exists, early restoration of perfusion is necessary to prevent or limit multiple organ dysfunction, as well as reduce mortality. Hypoperfusion results from loss of plasma volume into the interstitial space, decreased vascular tone, and myocardial depression. The increase in the cardiac output that is necessary to compensate for the diminished vascular tone may be limited by the myocardial depression.",
"   </p>",
"   <p>",
"    Goals during the first six hours of fluid resuscitation, as suggested by the Surviving Sepsis Campaign Guidelines, include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Central venous pressure 8 to 12 mmHg",
"     </li>",
"     <li>",
"      Central venous (superior vena cava) or mixed venous oxygen saturation 70 or 65 percent, respectively",
"     </li>",
"     <li>",
"      Mean arterial pressure &ge;65 mmHg",
"     </li>",
"     <li>",
"      Urine output &ge;0.5",
"      <span class=\"nowrap\">",
"       mL/kg/hour",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Resuscitation of the circulation should target a central or mixed venous oxyhemoglobin saturation (ScvO",
"    <sub>",
"     2",
"    </sub>",
"    or SvO",
"    <sub>",
"     2",
"    </sub>",
"    ) of &ge;70 or 65 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/10,14\">",
"     10,14",
"    </a>",
"    ]. The focus on the ScvO",
"    <sub>",
"     2",
"    </sub>",
"    derives from a clinical trial in which 263 patients with severe sepsis or septic shock were randomly assigned to therapy targeting a ScvO",
"    <sub>",
"     2",
"    </sub>",
"    &ge;70 percent, or conventional therapy that did not target a ScvO",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/14\">",
"     14",
"    </a>",
"    ]. Both groups initiated therapy within six hours of presentation and targeted the same CVP, MAP, and urine output. Mortality was lower in the group that targeted a ScvO",
"    <sub>",
"     2",
"    </sub>",
"    &ge;70 percent (31 versus 47 percent). This approach is known as \"early goal-directed therapy\" (ie, administered within the first six hours of presentation).",
"   </p>",
"   <p>",
"    Earlier studies of critically ill patients that used similar targets (SvO",
"    <sub>",
"     2",
"    </sub>",
"    &ge;70 percent) found no mortality benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/25\">",
"     25",
"    </a>",
"    ]. This might be because these studies were not conducted during the crucial initial hours. This is supported by a systematic review that compared resuscitation targeting specific physiologic endpoints to standard resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/26\">",
"     26",
"    </a>",
"    ]. In a meta-analysis of randomized trials initiated within 24 hours of the onset of sepsis (6 trials, 740 patients), resuscitation targeting specific physiologic endpoints improved mortality compared to standard resuscitation (39 versus 57 percent, odds ratio 0.50, 95% CI 0.37-0.69). In contrast, a meta-analysis of randomized trials initiated more than 24 hours after the onset of sepsis (3 trials, 261 patients) found that resuscitation targeting specific physiologic endpoints did not improve mortality (64 versus 58 percent for standard resuscitation, odds ratio 1.16, 95% CI 0.60-2.22).",
"   </p>",
"   <p>",
"    The other goals outlined in the Surviving Sepsis Campaign, central venous pressure (CVP) 8 to 12 mmHg, a mean arterial pressure (MAP) &ge;65 mmHg, and a urine output &ge;0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour have not been as well studied as the ScvO",
"    <sub>",
"     2",
"    </sub>",
"    but are commonly used. Many clinicians prefer to use dynamic indices (eg, radial pulse pressure, aortic blood flow peak velocity, brachial artery blood flow velocity, or passive leg raising) to guide fluid resuscitation rather than static hemodynamic measures (ie, CVP, pulmonary artery occlusion pressure) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. We consider the numeric goals for CVP, MAP, and urine output to be guidelines and always consider additional clinical signs of hypoperfusion when assessing the patient's response to a therapy.",
"   </p>",
"   <p>",
"    The lactate clearance is defined by the equation [(initial lactate - lactate &gt;2 hours",
"    <span class=\"nowrap\">",
"     later)/initial",
"    </span>",
"    lactate] x 100. The lactate clearance has been evaluated as a potential substitute for ScvO",
"    <sub>",
"     2",
"    </sub>",
"    as the target of resuscitation. A trial randomly assigned 300 patients with severe sepsis to undergo resuscitation targeting either a lactate clearance &ge;10 percent or an ScvO",
"    <sub>",
"     2",
"    </sub>",
"    &ge;70 percent (other than these targets, the resuscitation protocols were identical) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/27\">",
"     27",
"    </a>",
"    ]. There was no difference in hospital mortality, length of stay, ventilator-free days, or incidence of multiorgan failure, suggesting that lactate clearance criteria may be an acceptable alternative to ScvO",
"    <sub>",
"     2",
"    </sub>",
"    criteria.",
"   </p>",
"   <p>",
"    In our practice, we prefer to target an ScvO",
"    <sub>",
"     2",
"    </sub>",
"    &ge;70 percent because it is the more extensively studied resuscitation goal, although a lactate clearance &ge;10 percent appears to be a reasonable alternative if ScvO",
"    <sub>",
"     2",
"    </sub>",
"    monitoring is unavailable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3877618\">",
"    <span class=\"h2\">",
"     Interventions to restore perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restoration of perfusion is predominantly focused on administration of intravenous fluids; additional modalities such as vasopressor therapy, inotropic therapy, and blood transfusion are added, depending on the response to fluid resuscitation, evidence for myocardial dysfunction, and presence of anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Intravenous fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relative intravascular hypovolemia is typical and may be severe. As an example, early goal-directed therapy required a mean infusion volume of approximately five liters within the initial six hours of therapy in the trial described above [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/14\">",
"     14",
"    </a>",
"    ]. As a result, rapid, large volume infusions of intravenous fluids are indicated as initial therapy for severe sepsis or septic shock, unless there is coexisting clinical or radiographic evidence of heart failure.",
"   </p>",
"   <p>",
"    Fluid therapy should be administered in well-defined (eg, 500 mL), rapidly infused boluses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Volume status, tissue perfusion, blood pressure, and the presence or absence of pulmonary edema must be assessed before and after each bolus. Intravenous fluid challenges can be repeated until blood pressure is acceptable, tissue perfusion is acceptable, pulmonary edema ensues, or fluid fails to augment perfusion.",
"   </p>",
"   <p>",
"    Careful monitoring is essential in this approach because patients with sepsis typically develop noncardiogenic pulmonary edema (ie, ARDS). In patients with ARDS who are hemodynamically resuscitated, a liberal approach to intravenous fluid administration prolongs the duration of mechanical ventilation, compared to a more restrictive approach that typically requires large doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/28\">",
"     28",
"    </a>",
"    ]. Thus, while the early, aggressive fluid therapy is appropriate in severe sepsis and septic shock, fluids may be unhelpful or harmful when the circulation is no longer fluid-responsive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link&amp;anchor=H15#H15\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\", section on 'Fluid management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized trials have found no difference between using albumin and a crystalloid solution (eg, normal saline, Ringer&rsquo;s lactate) in the treatment of severe sepsis or septic shock, but they have identified potential harm from using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/27/14772?source=see_link\">",
"     pentastarch",
"    </a>",
"    or hydroxyethyl starch rather than a crystalloid solution:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Crystalloid versus albumin: In the saline versus albumin fluid evaluation (SAFE) trial, 6997 critically ill patients were randomly assigned to receive 4 percent albumin or normal saline for up to 28 days [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/29\">",
"       29",
"      </a>",
"      ]. There were no differences between groups for any endpoint, including the primary endpoint, mortality. Among the patients with severe sepsis (18 percent of the total group), there were also no differences in outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Crystalloid versus hydroxyethyl starch: In the Scandinavian Starch for Severe Sepsis and Septic Shock (6S) trial, 804 patients with severe sepsis were randomly assigned to receive either 6 percent hydroxyethyl starch or Ringer&rsquo;s acetate at a volume of up to 33",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of ideal body weight per day [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/30\">",
"       30",
"      </a>",
"      ]. When assessed 90 days after randomization, mortality was increased in the hydroxyethyl starch group (51 versus 43 percent) and more patients in the hydroxyethyl starch group had required renal replacement therapy at some time during their illness (22 versus 16 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Crystalloid versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/27/14772?source=see_link\">",
"       pentastarch",
"      </a>",
"      : The Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP) trial compared pentastarch to modified Ringer's lactate in patients with severe sepsis and found no difference in 28-day mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/31\">",
"       31",
"      </a>",
"      ]. The trial was stopped early because there was a trend toward increased 90-day mortality among patients who received pentastarch.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our clinical practices, we generally use a crystalloid solution instead of albumin because of the higher cost of albumin. We believe that giving a sufficient quantity of intravenous fluids rapidly and targeting appropriate goals is more important than the type of fluid chosen. We do not use hydroxyethyl starch or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/27/14772?source=see_link\">",
"     pentastarch",
"    </a>",
"    . These choices are consistent with current guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Choice of replacement fluid'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Vasopressors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopressors are second line agents in the treatment of severe sepsis and septic shock; we prefer intravenous fluids as long as they increase perfusion without seriously impairing gas exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/32\">",
"     32",
"    </a>",
"    ]. However, intravenous vasopressors are useful in patients who remain hypotensive despite adequate fluid resuscitation or who develop cardiogenic pulmonary edema.",
"   </p>",
"   <p>",
"    In severe septic shock, we prefer to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"     norepinephrine",
"    </a>",
"    in most patients (",
"    <a class=\"graphic graphic_table graphicRef74872 \" href=\"UTD.htm?23/43/24251\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/7,10,33\">",
"     7,10,33",
"    </a>",
"    ]. However, we find",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    (a pure alpha-adrenergic agonist) to be useful when tachycardia or arrhythmias preclude the use of agents with beta-adrenergic activity. Choosing a vasopressor agent is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link&amp;anchor=H35#H35\">",
"     \"Use of vasopressors and inotropes\", section on 'Choice of agent in septic shock'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Additional therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the ScvO",
"    <sub>",
"     2",
"    </sub>",
"    remains &lt;70 percent after optimization of intravenous fluid and vasopressor therapy, it is reasonable to consider additional therapies, such as inotropic therapy or red blood cell transfusion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inotropic therapy &ndash; For patients who have diminished cardiac output, a trial of inotropic therapy is warranted if ScvO",
"      <sub>",
"       2",
"      </sub>",
"      remains &lt;70 percent after all of the interventions discussed above [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/7,8,14,34,35\">",
"       7,8,14,34,35",
"      </a>",
"      ]. Inotropic therapy should not be used to increase the cardiac index to supranormal levels [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/7\">",
"       7",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       Dobutamine",
"      </a>",
"      is the usual inotropic agent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/10\">",
"       10",
"      </a>",
"      ]. At low doses, dobutamine may cause the blood pressure to decrease because it can dilate the systemic arteries. However, as the dose is increased, blood pressure usually rises because cardiac output increases out of proportion to the fall in vascular resistance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link&amp;anchor=H21#H21\">",
"       \"Use of vasopressors and inotropes\", section on 'Dobutamine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Red blood cell transfusions &ndash; The ideal threshold for red blood cell transfusion in patients with sepsis is not known [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/36\">",
"       36",
"      </a>",
"      ]. Early goal-directed therapy, as described above, aggressively utilized red blood cell transfusions to raise the ScvO",
"      <sub>",
"       2",
"      </sub>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/14\">",
"       14",
"      </a>",
"      ]. Nearly 70 percent of patients in the early goal-directed therapy group received transfusions, compared to 45 percent in the conventional therapy group, suggesting a beneficial effect of transfusions [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/14\">",
"       14",
"      </a>",
"      ]. In a separate observational study of 1054 patients with severe sepsis or septic shock, transfused patients had a lower risk of 7 and 28-day mortality (hazard ratio [HR] 0.42, 95% CI 0.19-0.50 and HR 0.43, 95% CI 0.29-0.62, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/37\">",
"       37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, other data support a more cautious approach to transfusion in critically ill patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/38\">",
"       38",
"      </a>",
"      ]. There are several possible explanations for the conflicting data:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Outcome may be related to when a red blood cell transfusion is given. Transfusions administered as part of early goal-directed therapy were given early in the course of illness, whereas studies that support a more cautious approach typically gave transfusions later in the course of illness.",
"     </li>",
"     <li>",
"      The apparent benefit of red blood cell transfusions may be due to other interventions. In other words, red blood cell transfusion was just one of several interventions during early goal-directed therapy and it is possible that the benefit was due to one or more of the other interventions, not the red blood cell transfusion per se [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of underlying coronary artery disease may affect individual tolerance of restrictive blood transfusion policies [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of blood transfusions in critically-ill patients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=see_link&amp;anchor=H2#H2\">",
"     \"Use of blood products in the critically ill\", section on 'Red blood cells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ongoing management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two possible outcomes following the interventions described above:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite aggressive therapy, the patient may have persistent hypoperfusion and progressive organ failure. This should prompt reassessment of the adequacy of the above therapies, antimicrobial regimen, and control of the septic focus, as well as the accuracy of the diagnosis and the possibility that unexpected complications or coexisting problems have intervened (eg, pneumothorax following CVC insertion).",
"     </li>",
"     <li>",
"      The patient may have responded to the above interventions with restored perfusion and a ScvO",
"      <sub>",
"       2",
"      </sub>",
"      greater than 70 percent. Such patients should continue to have their clinical and laboratory parameters followed closely. These include blood pressure, arterial lactate, urine output, creatinine, platelet count, Glasgow coma scale score, serum bilirubin, liver enzymes, oxygenation (ie, arterial oxygen tension or oxyhemoglobin saturation), and gut function (",
"      <a class=\"graphic graphic_table graphicRef72397 \" href=\"UTD.htm?13/55/14203\">",
"       table 4",
"      </a>",
"      ). Reevaluation is indicated if any of these parameters worsen or fail to improve.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In early sepsis, most lactate is probably a byproduct of anaerobic metabolism due to organ hypoperfusion. Supporting this view, early goal-directed therapy decreases lactate levels faster than conventional therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/14\">",
"     14",
"    </a>",
"    ]. After the restoration of perfusion, however, lactate is probably due to causes other than anaerobic metabolism and further increasing oxygen delivery to the peripheral tissues is unlikely to decrease its levels [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/39\">",
"     39",
"    </a>",
"    ]. As a result, lactate values are generally unhelpful following restoration of perfusion, with one exception &ndash; a rising lactate level should prompt reevaluation of perfusion (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/35/13877?source=see_link\">",
"     \"Venous blood gases and other alternatives to arterial blood gases\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It would be ideal if hypoxia could be detected for individual organs, because tests that combine output from many organs (eg, arterial lactate) may obscure the presence of significant ischemia in an individual organ [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/40\">",
"     40",
"    </a>",
"    ]. Gastric tonometry indirectly measures perfusion to the gut by estimating the gastric mucosal PCO",
"    <sub>",
"     2",
"    </sub>",
"    . It can be used to detect gut hypoxia by calculating the gastric to arterial PCO",
"    <sub>",
"     2",
"    </sub>",
"    gap [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. But, gastric tonometry is not widely available and it is uncertain whether it can successfully guide therapy. Additional studies and clinical experience are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CONTROL OF THE SEPTIC FOCUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt identification and treatment of the primary site or sites of infection are essential [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. This is the primary therapeutic intervention, with most other interventions being purely supportive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Identification of the septic focus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful history and physical examination may yield clues to the source of sepsis and help guide microbiologic evaluation (",
"    <a class=\"graphic graphic_table graphicRef59769 \" href=\"UTD.htm?2/26/2477\">",
"     table 5",
"    </a>",
"    ). As an example, sepsis arising after trauma or surgery is often due to infection at the site of injury or surgery. The presence of a urinary or vascular catheter increases the chances that these are the source of sepsis.",
"   </p>",
"   <p>",
"    Gram stain of material from sites of possible infection may give early clues to the etiology of infection while cultures are incubating. As examples, urine should be routinely Gram stained and cultured, sputum should be examined in a patient with a productive cough, and an intra-abdominal collection in a postoperative patient should be percutaneously sampled under ultrasound or radiologic guidance.",
"   </p>",
"   <p>",
"    Blood should be taken from two distinct venipuncture sites and inoculated into standard blood culture media (aerobic and anaerobic). For patients with a vascular catheter, blood should be obtained through the catheter and from another site [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11494?source=see_link\">",
"     \"Blood cultures for the detection of bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If invasive candida or aspergillus infection is suspected, serologic assays for 1,3 beta-D-glucan, galactomannan, and anti-mannan antibodies, if available, may provide early evidence of these fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/10\">",
"     10",
"    </a>",
"    ]. The limitations of these assays and their role in the diagnosis of fungal infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\", section on 'Non-culture methods'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link&amp;anchor=H1064486430#H1064486430\">",
"     \"Diagnosis of invasive aspergillosis\", section on 'Galactomannan antigen detection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link&amp;anchor=H1064486465#H1064486465\">",
"     \"Diagnosis of invasive aspergillosis\", section on 'Beta-D-glucan assay'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no single test that immediately confirms the diagnosis of severe sepsis or septic shock. However, several laboratory tests, all of which are still investigational, have been studied as diagnostic markers of active bacterial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated serum procalcitonin levels are associated with bacterial infection and sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/46-48\">",
"       46-48",
"      </a>",
"      ]. Despite this, a meta-analysis of 18 studies found that procalcitonin distinguished sepsis from nonseptic systemic inflammation poorly (sensitivity of 71 percent and specificity of 71 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/47\">",
"       47",
"      </a>",
"      ] and another meta-analysis of six trials (four in patients with sepsis and two in patients with other infections) found that using clinical algorithms based upon procalcitonin levels did not affect mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The plasma concentration of soluble TREM-1 (triggering receptor expressed on myeloid cells), a member of the immunoglobulin superfamily that is specifically upregulated in the presence of bacterial products, is increased in patients with sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/50-52\">",
"       50-52",
"      </a>",
"      ]. In a small trial, increased TREM-1 levels were both sensitive and specific for the diagnosis of bacterial sepsis (96 and 89 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/50\">",
"       50",
"      </a>",
"      ]. However, a subsequent prospective cohort study found that increased TREM-1 levels predicted sepsis with a sensitivity and specificity of only 53 and 86 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/53\">",
"       53",
"      </a>",
"      ]. Serial monitoring of TREM-1 may also provide prognostic information in patients with established sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/51,52\">",
"       51,52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased expression of CD64 on polymorphonuclear leukocytes indicates cellular activation and has been shown to occur in patients with sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. In a prospective cohort study of 300 consecutive critically ill patients, increased CD64 expression predicted sepsis with a sensitivity of 84 percent and a specificity of 95 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/53\">",
"       53",
"      </a>",
"      ]. In this study, the sensitivity and specificity of increased CD64 expression were superior to that of increased procalcitonin or TREM-1 levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combination of procalcitonin levels, TREM-1 levels, and CD64 expression appears to be superior to the use of any of these markers alone. However, evaluation of the clinical usefulness of such biomarkers is still in its earliest stages and should be considered preliminary. Until additional clinical investigations have been performed, we do not suggest the routine use of such biomarkers to identify sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Eradication of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt and effective treatment of the active infection is essential to the successful treatment of severe sepsis and septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/10\">",
"     10",
"    </a>",
"    ]. Source control (physical measures undertaken to eradicate a focus of infection and eliminate or treat ongoing microbial proliferation and infection) should be undertaken since undrained foci of infection may not respond to antibiotics alone (",
"    <a class=\"graphic graphic_table graphicRef58257 \" href=\"UTD.htm?6/4/6220\">",
"     table 2",
"    </a>",
"    ). As examples, potentially infected foreign bodies (eg, vascular access devices) should be removed when possible, and abscesses should undergo percutaneous or surgical drainage. Some patients require extensive soft tissue debridement or amputation; in severe cases, fulminant Clostridium difficile-associated colitis may necessitate colectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Antimicrobial regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous antibiotic therapy should be initiated immediately after obtaining appropriate cultures, since early initiation of antibiotic therapy is associated with lower mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/57\">",
"     57",
"    </a>",
"    ]. The choice of antibiotics can be complex and should consider the patient's history (eg, recent antibiotics received [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/58\">",
"     58",
"    </a>",
"    ]), comorbidities, clinical context (eg, community- or hospital-acquired), Gram stain data, and local resistance patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/7,59,60\">",
"     7,59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poor outcomes are associated with inadequate or inappropriate antimicrobial therapy (ie, treatment with antibiotics to which the pathogen was later shown to be resistant in vitro) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/61-67\">",
"     61-67",
"    </a>",
"    ]. They are also associated with delays in initiating antimicrobial therapy, even short delays (eg, an hour).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective cohort study of 2124 patients demonstrated that inappropriate antibiotic selection was surprisingly common (32 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/64\">",
"       64",
"      </a>",
"      ]. Mortality was markedly increased in these patients compared to those who had received appropriate antibiotics (34 versus 18 percent).",
"     </li>",
"     <li>",
"      A retrospective analysis of 2731 patients with septic shock demonstrated that the time to initiation of appropriate antimicrobial therapy was the strongest predictor of mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the potential pathogen or infection source is not immediately obvious, we favor broad-spectrum antibiotic coverage directed against both gram-positive and gram-negative bacteria. Few guidelines exist for the initial selection of empiric antibiotics in severe sepsis or septic shock.",
"   </p>",
"   <p>",
"    Staphylococcus aureus is associated with significant morbidity if not treated early in the course of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/68\">",
"     68",
"    </a>",
"    ]. There is growing recognition that methicillin-resistant S. aureus (MRSA) is a cause of sepsis not only in hospitalized patients, but also in community dwelling individuals without recent hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. &nbsp;For these reasons, we recommend that severely ill patients presenting with sepsis of unclear etiology be treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (adjusted for renal function) until the possibility of MRSA sepsis has been excluded. Potential alternative agents to vancomycin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    for non-pulmonary MRSA,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     ceftaroline",
"    </a>",
"    ) should be considered for patients with refractory or virulent MRSA, or a contraindication to vancomycin. These agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\", section on 'Bacteremia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Methicillin-resistant Staphylococcus aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our practice, if Pseudomonas is an unlikely pathogen, we favor combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    with one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cephalosporin, 3rd generation (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      ), or",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Beta-lactam/beta-lactamase",
"      </span>",
"      inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      ), or",
"     </li>",
"     <li>",
"      Carbapenem (eg, imipenem or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternatively, if Pseudomonas is a possible pathogen, we favor combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    with two of the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=see_link\">",
"     \"Treatment of Pseudomonas aeruginosa infections\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antipseudomonal cephalosporin (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      ), or",
"     </li>",
"     <li>",
"      Antipseudomonal carbapenem (eg, imipenem,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      ), or",
"     </li>",
"     <li>",
"      Antipseudomonal",
"      <span class=\"nowrap\">",
"       beta-lactam/beta-lactamase",
"      </span>",
"      inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      ), or",
"     </li>",
"     <li>",
"      Fluoroquinolone with good anti-pseudomonal activity (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      ), or",
"     </li>",
"     <li>",
"      Aminoglycoside (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      ), or",
"     </li>",
"     <li>",
"      Monobactam (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Selection of two agents from the same class, for example, two beta-lactams, should be avoided. We emphasize the importance of considering local susceptibility patterns when choosing an empiric antibiotic regimen.",
"   </p>",
"   <p>",
"    After culture results and antimicrobial susceptibility data return, we recommend that therapy be pathogen- and susceptibility-directed, even if there has been clinical improvement while on the initial antimicrobial regimen. Gram-negative pathogens have historically been covered with two agents from different antibiotic classes. However, several clinical trials and two meta-analyses have failed to demonstrate superior overall efficacy of combination therapy compared to monotherapy with a third generation cephalosporin or a carbapenem [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/64,71-75\">",
"     64,71-75",
"    </a>",
"    ]. Furthermore, one meta-analysis found double coverage was associated with an increased incidence of adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. For this reason, we recommend use of a single agent with proven efficacy and the least possible toxicity, except in patients who are either neutropenic or whose severe sepsis is due to a known or suspected Pseudomonas infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/7,73\">",
"     7,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14775?source=see_link\">",
"     \"Pseudomonas aeruginosa bacteremia and endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=see_link\">",
"     \"Treatment of Pseudomonas aeruginosa infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the antibiotic regimen selected, patients should be observed closely for toxicity, evidence of response, and the development of nosocomial superinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/76\">",
"     76",
"    </a>",
"    ]. There are no published randomized controlled trials testing safety of de-escalation of antibiotic therapy in adult patients with sepsis or septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/77\">",
"     77",
"    </a>",
"    ]. The duration of therapy is typically 7 to 10 days, although longer courses may be appropriate in patients who have a slow clinical response, an undrainable focus of infection, or immunologic deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/7\">",
"     7",
"    </a>",
"    ]. In patients who are neutropenic, antibiotic treatment should continue until the neutropenia has resolved or the planned antibiotic course is complete, whichever is longer. In non-neutropenic patients in whom infection is thoroughly excluded, antibiotics should be discontinued to minimize colonization or infection with drug-resistant microorganisms and superinfection with other pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ADDITIONAL THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have long been investigated as therapeutic agents in sepsis because the pathogenesis of sepsis involves an intense and potentially deleterious host inflammatory response. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=see_link\">",
"     \"Corticosteroid therapy in septic shock\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is consensus that nutritional support improves nutritional outcomes in critically ill patients, such as body weight and mid-arm muscle mass. However, it is uncertain whether nutritional support improves important clinical outcomes (eg, duration of mechanical ventilation, length of stay, mortality), or when nutritional support should be initiated. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Intensive insulin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemia and insulin resistance are common in critically ill patients, independent of a history of diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/78\">",
"     78",
"    </a>",
"    ]. As a result, intensive glycemic control has been studied and a body of evidence has accumulated. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15515263\">",
"    <span class=\"h2\">",
"     External cooling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlling fever during severe sepsis and septic shock has potential benefits and adverse effects, the net effects of which are uncertain. A trial was performed to compare the effects of external cooling with no external cooling. External cooling consists of using either an automatic cooling blanket, or ice-cold bed sheets and ice packs, to achieve a core body temperature of 36.5 to 37&ordm;C for 48 hours. It decreases the time to fever control without exposing the patient to potential adverse effects of antipyretic drugs.",
"   </p>",
"   <p>",
"    The trial randomly assigned 200 patients with septic shock (the patients were requiring vasopressors, mechanically ventilated, and sedated) to receive either external cooling or no external cooling [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/79\">",
"     79",
"    </a>",
"    ]. Patients in the external cooling group had lower 14-day mortality (19 versus 34 percent) and were more likely to have their vasopressor dose lowered by 50 percent (54 versus 20 percent) and their shock reversed during their ICU stay (86 versus 73 percent). No antipyretic agents were received during the trial.",
"   </p>",
"   <p>",
"    While these results are promising, we believe that the results need to be confirmed before external cooling is adopted as routine clinical practice. Among the limits of the trial, patients in the external cooling group may have been less severely ill (ie, they required a lower baseline vasopressor dose), the trial was not blinded so co-interventions cannot be excluded, and there were relatively few events (ie, deaths, patients with a 50 percent vasopressor dose decrease, and patients with shock reversal), which lowers confidence in the accuracy of the estimated effects. Moreover, the results suggest that external cooling is preferable to no cooling, but they do not provide guidance about whether external cooling is preferable to antipyretic medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis treatment protocols may improve outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. This was illustrated by an observational cohort study of 120 patients with septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?20/51/21306/abstract/82\">",
"     82",
"    </a>",
"    ]. Implementation of a standardized hospital order set was associated with greater likelihood that the initial antibiotic regimen targeted the culprit microorganism (87 versus 72 percent), shorter hospital stay (9 versus 12 days), and lower 28-day mortality (30 versus 48 percent), compared to historical controls. It is impossible to determine which component or components of the protocol conferred the benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=see_link\">",
"       \"Patient information: Sepsis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sepsis is a clinical syndrome characterized by systemic inflammation and widespread tissue injury due to infection. There is a continuum of illness severity ranging from sepsis to severe sepsis and septic shock. When infection is absent, the clinical syndrome is termed systemic inflammatory response syndrome (SIRS). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial management is aimed at securing the airway and correcting hypoxemia. Intubation and mechanical ventilation may be required. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Stabilize respiration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the patient's respiratory status has been stabilized, the adequacy of perfusion should be assessed. Hypotension is the most common indicator that perfusion is inadequate. However, critical hypoperfusion can also occur in the absence of hypotension, especially during early sepsis. Common signs of hypoperfusion include cool, vasoconstricted skin due to redirection of blood flow to core organs (although warm, flushed skin may be present in the early phases of sepsis), obtundation or restlessness, oliguria or anuria, and lactic acidosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Assess perfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once it has been established that hypoperfusion exists, early restoration of perfusion is necessary to prevent or limit multiple organ dysfunction, as well as reduce mortality. Tissue perfusion should be promptly restored using intravenous fluids, vasopressors, inotropes, and, possibly, red blood cell transfusions. We recommend that patients be managed with therapy aimed at achieving a central venous oxygen saturation &ge;70 percent, or mixed venous oxygen saturation &ge;65 percent, within six hours of presentation, rather than being managed without specific therapeutic targets (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). A strategy that targets a lactate clearance &ge;10 percent is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H3877337\">",
"       'Goals of initial resuscitation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3877618\">",
"       'Interventions to restore perfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend boluses of intravenous fluids as first-line therapy in patients who demonstrate impaired perfusion (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Fluid boluses are repeated until blood pressure and tissue perfusion are acceptable, pulmonary edema ensues, or there is no further response. These parameters should be assessed before and after each fluid bolus. For initial fluid replacement, we recommend using a crystalloid solution rather than a hyperoncotic starch solution (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ), and we suggest using a crystalloid rather than albumin-containing solution (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Intravenous fluids'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Choice of replacement fluid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend vasopressors for patients who remain hypotensive following intravascular volume repletion (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ); the preferred initial agent is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"       norepinephrine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Vasopressors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link&amp;anchor=H35#H35\">",
"       \"Use of vasopressors and inotropes\", section on 'Choice of agent in septic shock'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients whose ScvO",
"      <sub>",
"       2",
"      </sub>",
"      remains &lt;70 percent after intravenous fluid and vasopressor therapy, additional therapies, such as inotropic therapy or blood transfusions, are administered based on individual assessment. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Additional therapies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link&amp;anchor=H35#H35\">",
"       \"Use of vasopressors and inotropes\", section on 'Choice of agent in septic shock'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prompt identification and treatment of the site of infection are essential. Sputum and urine should be collected for Gram stain and culture. Intra-abdominal fluid collections should be percutaneously sampled. Blood should be taken from two distinct venipuncture sites and from indwelling vascular access devices and cultured aerobically and anaerobically. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Identification of the septic focus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotics should be administered immediately after appropriate cultures have been obtained. We recommend empiric broad spectrum antibiotics when a definite source of infection can not be identified (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Antimicrobial regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potentially infected vascular access devices should be removed (if possible), abscesses should be drained, and extensive soft tissue infections should be debrided or amputated (",
"      <a class=\"graphic graphic_table graphicRef58257 \" href=\"UTD.htm?6/4/6220\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Eradication of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoid therapy, nutritional support, and glucose control are additional issues that are important in the management of patients with severe sepsis or septic shock. Each is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=see_link\">",
"       \"Corticosteroid therapy in septic shock\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"       \"Nutrition support in critically ill patients: An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"       \"Glycemic control and intensive insulin therapy in critical illness\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Elixhauser A, Friedman B, Stranges E. Septicemia in U.S. Hospitals, 2009. Agency for Healthcare Research and Quality, Rockville, MD. file://www.hcup-us.ahrq.gov/reports/statbriefs/sb122.pdf (Accessed on February 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/2\">",
"      Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/3\">",
"      McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994; 121:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/4\">",
"      Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997; 25:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/5\">",
"      Sasse KC, Nauenberg E, Long A, et al. Long-term survival after intensive care unit admission with sepsis. Crit Care Med 1995; 23:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/6\">",
"      Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/7\">",
"      Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/8\">",
"      Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004; 32:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/9\">",
"      Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 1999; 27:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/10\">",
"      Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/11\">",
"      Sessler CN, Perry JC, Varney KL. Management of severe sepsis and septic shock. Curr Opin Crit Care 2004; 10:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/12\">",
"      Luce JM. Pathogenesis and management of septic shock. Chest 1987; 91:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/13\">",
"      Ghosh S, Latimer RD, Gray BM, et al. Endotoxin-induced organ injury. Crit Care Med 1993; 21:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/14\">",
"      Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/15\">",
"      Michard F, Boussat S, Chemla D, et al. Relation between respiratory changes in arterial pulse pressure and fluid responsiveness in septic patients with acute circulatory failure. Am J Respir Crit Care Med 2000; 162:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/16\">",
"      Walley KR. Use of central venous oxygen saturation to guide therapy. Am J Respir Crit Care Med 2011; 184:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/17\">",
"      Harvey S, Harrison DA, Singer M, et al. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet 2005; 366:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/18\">",
"      Richard C, Warszawski J, Anguel N, et al. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2003; 290:2713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/19\">",
"      National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wheeler AP, Bernard GR, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/20\">",
"      Brennan JM, Blair JE, Hampole C, et al. Radial artery pulse pressure variation correlates with brachial artery peak velocity variation in ventilated subjects when measured by internal medicine residents using hand-carried ultrasound devices. Chest 2007; 131:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/21\">",
"      Eikermann M, Magder S, Malhotra A. Is brachial artery peak velocity variation ready for prime time? Chest 2007; 131:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/22\">",
"      Monnet X, Rienzo M, Osman D, et al. Esophageal Doppler monitoring predicts fluid responsiveness in critically ill ventilated patients. Intensive Care Med 2005; 31:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/23\">",
"      Reuter DA, Bayerlein J, Goepfert MS, et al. Influence of tidal volume on left ventricular stroke volume variation measured by pulse contour analysis in mechanically ventilated patients. Intensive Care Med 2003; 29:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/24\">",
"      Cavallaro F, Sandroni C, Marano C, et al. Diagnostic accuracy of passive leg raising for prediction of fluid responsiveness in adults: systematic review and meta-analysis of clinical studies. Intensive Care Med 2010; 36:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/25\">",
"      Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 1995; 333:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/26\">",
"      Jones AE, Brown MD, Trzeciak S, et al. The effect of a quantitative resuscitation strategy on mortality in patients with sepsis: a meta-analysis. Crit Care Med 2008; 36:2734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/27\">",
"      Jones AE, Shapiro NI, Trzeciak S, et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA 2010; 303:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/28\">",
"      National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/29\">",
"      Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/30\">",
"      Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/31\">",
"      Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125.",
"     </a>",
"    </li>",
"    <li>",
"     Reinhart K, Bloos F, Spies C. Vasoactive drug therapy in sepsis. In: Clinical Trials for the treatment of sepsis, Sibbald WJ, Vincent JL (Eds), Springer Verlag, Berlin 1995. p.207.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/33\">",
"      De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/34\">",
"      Rhodes A, Bennett ED. Early goal-directed therapy: an evidence-based review. Crit Care Med 2004; 32:S448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/35\">",
"      Bersten AD, Hersch M, Cheung H, et al. The effect of various sympathomimetics on the regional circulations in hyperdynamic sepsis. Surgery 1992; 112:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/36\">",
"      Vincent JL. Transfusion triggers: getting it right! Crit Care Med 2012; 40:3308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/37\">",
"      Park DW, Chun BC, Kwon SS, et al. Red blood cell transfusions are associated with lower mortality in patients with severe sepsis and septic shock: a propensity-matched analysis*. Crit Care Med 2012; 40:3140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/38\">",
"      H&eacute;bert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/39\">",
"      Forsythe SM, Schmidt GA. Sodium bicarbonate for the treatment of lactic acidosis. Chest 2000; 117:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/40\">",
"      Third European Consensus Conference in Intensive Care Medicine. Tissue hypoxia: How to detect, how to correct, how to prevent. Soci&eacute;t&eacute; de R&eacute;animation de Langue Fran&ccedil;aise. The American Thoracic Society. European Society of Intensive Care Medicine. Am J Respir Crit Care Med 1996; 154:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/41\">",
"      Gutierrez G, Palizas F, Doglio G, et al. Gastric intramucosal pH as a therapeutic index of tissue oxygenation in critically ill patients. Lancet 1992; 339:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/42\">",
"      Poeze M, Solberg BC, Greve JW, Ramsay G. Monitoring global volume-related hemodynamic or regional variables after initial resuscitation: What is a better predictor of outcome in critically ill septic patients? Crit Care Med 2005; 33:2494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/43\">",
"      Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/44\">",
"      Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995; 274:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/45\">",
"      Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/46\">",
"      Clec'h C, Fosse JP, Karoubi P, et al. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med 2006; 34:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/47\">",
"      Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007; 7:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/48\">",
"      Ruiz-Alvarez MJ, Garc&iacute;a-Valdecasas S, De Pablo R, et al. Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis. J Intensive Care Med 2009; 24:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/49\">",
"      Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011; 171:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/50\">",
"      Gibot S, Kolopp-Sarda MN, B&eacute;n&eacute; MC, et al. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 2004; 141:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/51\">",
"      Gibot S, Cravoisy A, Kolopp-Sarda MN, et al. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med 2005; 33:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/52\">",
"      Gibot S, Le Renard PE, Bollaert PE, et al. Surface triggering receptor expressed on myeloid cells 1 expression patterns in septic shock. Intensive Care Med 2005; 31:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/53\">",
"      Gibot S, B&eacute;n&eacute; MC, Noel R, et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 2012; 186:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/54\">",
"      Groselj-Grenc M, Ihan A, Pavcnik-Arnol M, et al. Neutrophil and monocyte CD64 indexes, lipopolysaccharide-binding protein, procalcitonin and C-reactive protein in sepsis of critically ill neonates and children. Intensive Care Med 2009; 35:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/55\">",
"      Cardelli P, Ferraironi M, Amodeo R, et al. Evaluation of neutrophil CD64 expression and procalcitonin as useful markers in early diagnosis of sepsis. Int J Immunopathol Pharmacol 2008; 21:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/56\">",
"      Seder CW, Villalba MR Jr, Robbins J, et al. Early colectomy may be associated with improved survival in fulminant Clostridium difficile colitis: an 8-year experience. Am J Surg 2009; 197:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/57\">",
"      Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/58\">",
"      Johnson MT, Reichley R, Hoppe-Bauer J, et al. Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis. Crit Care Med 2011; 39:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/59\">",
"      Verhoef J, Hustinx WM, Frasa H, Hoepelman AI. Issues in the adjunct therapy of severe sepsis. J Antimicrob Chemother 1996; 38:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/60\">",
"      Sibbald WJ, Vincent JL. Round table conference on clinical trials for the treatment of sepsis. Crit Care Med 1995; 23:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/61\">",
"      Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31:2742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/62\">",
"      Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/63\">",
"      Harbarth S, Garbino J, Pugin J, et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/64\">",
"      Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/65\">",
"      Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/66\">",
"      Schramm GE, Johnson JA, Doherty JA, et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment. Crit Care Med 2006; 34:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/67\">",
"      Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/68\">",
"      McDonald JR, Friedman ND, Stout JE, et al. Risk factors for ineffective therapy in patients with bloodstream infection. Arch Intern Med 2005; 165:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/69\">",
"      Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/70\">",
"      Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/71\">",
"      Rubinstein E, Lode H, Grassi C. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group. Clin Infect Dis 1995; 20:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/72\">",
"      Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother 1996; 40:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/73\">",
"      Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/74\">",
"      Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/75\">",
"      Paul M, Silbiger I, Grozinsky S, et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006; :CD003344.",
"     </a>",
"    </li>",
"    <li>",
"     Marshall J, Lowry S. Evaluation of the adequacy of source control. In: Clinical Trials for the treatment of sepsis, Sibbald WJ, Vincent JL (Eds), Springer Verlag, Berlin 1995. p.329.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/77\">",
"      Silva BN, Andriolo RB, Atallah AN, Salom&atilde;o R. De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev 2013; 3:CD007934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/78\">",
"      McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001; 17:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/79\">",
"      Schortgen F, Clabault K, Katsahian S, et al. Fever control using external cooling in septic shock: a randomized controlled trial. Am J Respir Crit Care Med 2012; 185:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/80\">",
"      Kortgen A, Niederpr&uuml;m P, Bauer M. Implementation of an evidence-based \"standard operating procedure\" and outcome in septic shock. Crit Care Med 2006; 34:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/81\">",
"      Shapiro NI, Howell MD, Talmor D, et al. Implementation and outcomes of the Multiple Urgent Sepsis Therapies (MUST) protocol. Crit Care Med 2006; 34:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/51/21306/abstract/82\">",
"      Micek ST, Roubinian N, Heuring T, et al. Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med 2006; 34:2707.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1613 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_51_21306=[""].join("\n");
var outline_f20_51_21306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THERAPEUTIC PRIORITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EARLY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Stabilize respiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Assess perfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Establish central venous access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3877337\">",
"      Goals of initial resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3877618\">",
"      Interventions to restore perfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Intravenous fluids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Vasopressors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Additional therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ongoing management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CONTROL OF THE SEPTIC FOCUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Identification of the septic focus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Eradication of infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Antimicrobial regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ADDITIONAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Intensive insulin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15515263\">",
"      External cooling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Protocols",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1613\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1613|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/32/7691\" title=\"table 1\">",
"      Mimics of sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/4/6220\" title=\"table 2\">",
"      Source control in sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/43/24251\" title=\"table 3\">",
"      Vasopressors in septic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/55/14203\" title=\"table 4\">",
"      Parameters during treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/26/2477\" title=\"table 5\">",
"      Evaluation of sources of sepsis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26424?source=related_link\">",
"      Arterial catheterization techniques for invasive monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11494?source=related_link\">",
"      Blood cultures for the detection of bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=related_link\">",
"      Complications of central venous catheters and their prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=related_link\">",
"      Corticosteroid therapy in septic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=related_link\">",
"      Diagnosis of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29960?source=related_link\">",
"      Investigational and ineffective therapies for sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=related_link\">",
"      Pathophysiology of sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=related_link\">",
"      Patient information: Sepsis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14775?source=related_link\">",
"      Pseudomonas aeruginosa bacteremia and endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=related_link\">",
"      Sedation or induction agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=related_link\">",
"      The decision to intubate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=related_link\">",
"      Treatment of Pseudomonas aeruginosa infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/35/13877?source=related_link\">",
"      Venous blood gases and other alternatives to arterial blood gases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_51_21307="Fredrickson classification";
var content_f20_51_21307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fredrickson classification of lipid disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Frederickson phenotype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lipoprotein abnormality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Typical lipid levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        Chylomicrons",
"       </td>",
"       <td>",
"        Triglycerides (TG) &gt;99th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        LDL",
"       </td>",
"       <td>",
"        Total cholesterol (TC) &gt;90th percentile; depending upon type, may also see TG and/or apolipoprotein B &ge;90th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        LDL and VLDL",
"       </td>",
"       <td>",
"        Depending upon type, TC and/or TG &ge;90th percentile and apolipoprotein B &ge;90th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Remnants of VLDL and chylomicrons",
"       </td>",
"       <td>",
"        TC and TG &gt;90th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        VLDL",
"       </td>",
"       <td>",
"        TC &gt;90th percentile; depending upon type, may also see TG &gt;90th percentile or low HDL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        V",
"       </td>",
"       <td>",
"        Chylomicrons and VLDL",
"       </td>",
"       <td>",
"        TG &gt;99th percentile",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Fredrickson DS. Ann Intern Med 1971; 75:471.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_51_21307=[""].join("\n");
var outline_f20_51_21307=null;
var title_f20_51_21308="Rx enterococci mening";
var content_f20_51_21308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antibiotic regimens for meningitis due to susceptible enterococcus strains*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Regimen",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dosage and route",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       One of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ampicillin&bull; (+/- sulbactam)",
"      </td>",
"      <td>",
"       12-18+ g per 24 hours in 6 equally divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Penicillin G",
"      </td>",
"      <td>",
"       18-30+ million units per 24 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vancomycin&Delta;",
"      </td>",
"      <td>",
"       30 mg/kg per 24 hours in 2 equally divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       <span class=\"red\">",
"        PLUS",
"       </span>",
"       one of the following&loz;:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gentamicin",
"      </td>",
"      <td>",
"       5.1 to 7 mg/kg per 24 hours (single daily dosing)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Streptomycin",
"      </td>",
"      <td>",
"       15 mg/kg per 24 hours (single daily dosing)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For patients failing to respond to systemic antibiotics, intraventricular vancomycin or gentamicin may be useful. Treatment of enterococcal meningitis caused by E faecium strains resistant to penicillin, aminoglycosides and vancomycin is a difficult challenge; intravenous linezolid or intravenous plus intraventricular quinupristin-dalfopristin are reasonable antibiotic choices, although experience with intraventricular administration is limited (See \"Infections of central nervous system shunts and other devices\").",
"     <br>",
"      &bull; The combination of ampicillin with ceftriaxone or imipenem may be considered, although data for this combination only exist for endocarditis.",
"      <br>",
"       &Delta; Vancomycin goal trough &gt;15 mcg/mL. An initial vancomycin loading dose of 25 to 30 mg/kg may be considered to reduce the time to achieve target trough concentrations for patients with serious infections such as meningitis. In addition, repeat CSF evaluation to evaluate for sterilization and vancomycin levels is advisable. Addition of rifampin (if susceptible) to vancomycin may also be considered.",
"       <br>",
"        &loz; No data exists to indicate that single dose aminoglycoside therapy is superior to divided dose therapy, but higher serum peaks may result in higher CSF levels. Serum aminoglycoside levels should be monitored:",
"        <br>",
"         Gentamicin goal peak 16 to 24 mcg per mL, goal trough &lt;1 mcg/mL",
"         <br>",
"          Streptomycin goal peak 56 to 64 mcg per mL, goal trough &lt;1 mcg/mL",
"          <br>",
"           If aminoglycosides are administered together with vancomycin, aminoglycoside dose reduction may be warranted to minimize toxicity",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_51_21308=[""].join("\n");
var outline_f20_51_21308=null;
var title_f20_51_21309="Uric acid crystals under polarized light";
var content_f20_51_21309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F73642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F73642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uric acid crystals under polarized light",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment showing uric acid crystals viewed under polarized light.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_51_21309=[""].join("\n");
var outline_f20_51_21309=null;
var title_f20_51_21310="Neuropathy screening instrument";
var content_f20_51_21310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F65776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F65776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Michigan Neuropathy Screening Instrument form",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 449px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17:1281.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_51_21310=[""].join("\n");
var outline_f20_51_21310=null;
var title_f20_51_21311="WHO MEC Personal characteristics and reproductive history";
var content_f20_51_21311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization medical eligibility for contraceptive use: Personal characteristics and reproductive history",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        COC",
"       </td>",
"       <td class=\"subtitle1\">",
"        CIC",
"       </td>",
"       <td class=\"subtitle1\">",
"        P/R",
"       </td>",
"       <td class=\"subtitle1\">",
"        POP",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         DMPA",
"        </p>",
"        <p>",
"         NET-EN",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         LNG/ETG",
"        </p>",
"        <p>",
"         Implants",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cu-IUD",
"       </td>",
"       <td class=\"subtitle1\">",
"        LNG-IUD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Menarche to &lt;18 yrs",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Menarche to &lt;20 yrs",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;20 yrs",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        18-45 yrs",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;40",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;40",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;45",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Parity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nulliparous",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parous",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Breastfeeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;6 weeks postpartum",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6 weeks to &lt;6 months (primarily breastfeeding)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;6 months postpartum",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Postpartum (non-breastfeeding women)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"9\">",
"        &lt;21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Without other risk factors for VTE",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        With other risk factors for VTE*",
"       </td>",
"       <td>",
"        3/4",
"       </td>",
"       <td>",
"        3/4",
"       </td>",
"       <td>",
"        3/4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"9\">",
"        &ge;21 days to 42 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Without other risk factors for VTE",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        With other risk factors for VTE*",
"       </td>",
"       <td>",
"        2/3",
"       </td>",
"       <td>",
"        2/3",
"       </td>",
"       <td>",
"        2/3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        &gt;42 days",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Postpartum (breastfeeding or nonbreastfeeding women, including post-caesarean section)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;48 hours",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1 if not breastfeeding, 3 if breastfeeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;48 hours to &lt;4 weeks",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;4 weeks",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Puerperal sepsis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Post-abortion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        First trimester",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Second trimester",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immediate post-septic abortion",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Past ectopic pregnancy",
"        </strong>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Smoking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Age &lt;35",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"9\">",
"        Age &ge;35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &lt;15 cigarettes/day",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &ge;15 cigarettes/day",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;30 kg/m",
"        <sup>",
"         2",
"        </sup>",
"        body mass index (BMI)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Menarche to age 18 and BMI &ge;30 kg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        <p>",
"         DMPA: 2",
"        </p>",
"        <p>",
"         NET-EN: 1",
"        </p>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    1: A condition for which there is no restriction for the use of the contraceptive method.",
"    <br>",
"     2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks.",
"     <br>",
"      3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method.",
"      <br>",
"       4: A condition which represents an unacceptable health risk if the contraceptive method is used.",
"       <div class=\"footnotes\">",
"        COC: low-dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen-only pill; DMPA: depot medroxyprogesterone acetate; NET-EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill; Cu-IUD: copper intrauterine device; LNG-IUD: levonorgestrel-releasing IUDs; E-IUD: copper-IUD for emergency contraception; BARR: barrier methods; FAB: fertility awareness-based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization.",
"        <br>",
"         * Risk factors for venous thromboembolism (VTE) include previous VTE, thrombophilia, immobility, transfusion at delivery, BMI &gt;30 kg/m",
"         <sup>",
"          2",
"         </sup>",
"         , postpartum hemorrhage, immediately postcesarean delivery, preeclampsia, or smoking.",
"        </br>",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Medical Eligibility Criteria for Contraceptive Use - 4th Ed. Available at: file://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf. Copyright &copy; 2009 World Health Organization. With updated information from: World Health Organization (WHO), Department of Reproductive Health and Research, Combined hormonal contraceptive use during the postpartum period, Geneva, January 2010.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_51_21311=[""].join("\n");
var outline_f20_51_21311=null;
